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Abstract
One of the biggest challenges in ion beam therapy is the mitigation of the impact of uncer-
tainties in the quality of treatment plans. Some of the strategies used to reduce this impact are
based on concepts developed decades ago for photon therapy. In this thesis novel methods and
concepts, tailored to the specific needs of ion beam therapy, are proposed which reduce the ef-
fect of uncertainties on treatment plans. This is done in two steps: First, we revisit the concept
of the Planning Target Volume and propose a novel method for its definition. This method
enhances robustness of treatment plans and reduces the amount of healthy tissue irradiated. In
a clinical situation this could translate into an enhancement of the tumor control probability
while reducing side effects. The concept of robust conformity (conformity in the presence of
uncertainties) is proposed along with a way to quantify it. Secondly,a method to select robust
beam angle configurations that also spare organs at risks is proposed. This combination is a
new conceptual layout to tackle the challenges of ion beam therapy and enhances its potential.
Zusammenfassung
Eine der gro¨ßten Herausforderungen in der Ionenstrahltherapie ist die Beschra¨nkung der
Einflu¨sse von Ungenauigkeiten in der Therapieplanung. Einige Strategien, die verwendet wer-
den, um diese Effekte zu verringern, basieren auf Konzepten die vor Jahrzehnten fu¨r die Pho-
tonentherapie entwickelt wurden. In der vorliegenden Arbeit werden neue Methoden und
Konzepte vorgestellt, die speziell auf die Anforderungen der Ionenstrahltherapie zugeschnit-
ten sind und die Auswirkungen von Ungenauigkeiten auf die Therapieplanung verringern. Dies
erfolgt in zwei Schritten: Zuerst untersuchen wir das Konzept des geplanten Targetvolumens
und schlagen eine neue Definition hierfu¨r vor. Diese erho¨ht die Robustheit der Therapieplanung
und reduziert die Menge von gesundem Gewebe, das bestrahlt wird. In klinischen Anwendungen
kann dies die Tumorkontrollrate erho¨hen, wa¨hrend gleichzeitig Nebenwirkungen verringert wer-
den. Das Konzept der robusten Konformita¨t (Konformita¨t bei vorliegenden Ungenauigkeiten)
wird zur Quantifizierung dieser Verbesserungen vorgeschlagen.
Im zweiten Schritt schlagen wir, aufbauend auf die Konzepte, die im ersten Teil eingefu¨hrt
wurden, eine Methode vor, mit der robuste Kombinationen von Strahlrichtungen ausgewa¨hlt
werden knnen, die auerdem Risikoorgane vermeiden. Die Verknu¨pfung dieser beiden Schritte
stellt ein neues Konzept dar, das die Herausforderungen der Ionenstrahltherapie u¨berwinden
kann und damit das Potential dieser Therapie erho¨ht.
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Preface
The work presented in this thesis deals with the problem of robustness in ion beam
treatment plans. There are many directions from which this problem can be tackled or
at least, studied. This work focuses on two of them: First is the concept of planning
target volume as a way to assure robust dose coverage in the target. The second is the
selection of beam angles as a way to provide robust plans while taking into account
sensitive structures.
Both works are built over the concept of Dynamic Target Definition which is pre-
sented and developed in Chapter 2. Chapter 3 uses some of these concepts to propose
a way to develop criteria for robust beam angle selections. More than just offering
algorithms to achieve a certain goal, the work presented in Chapters 2 and 3 introduces
a new conceptual layout for robust treatment planning. Chapter 4 rounds up this work
with a discussion and a summary of the conclusions as well as giving an outlook on the
topics that are left for further investigation.
In order to work and develop a study on concepts and algorithms for treatment
planning is mandatory to have a Treatment Planning System (TPS). Very few groups
nowadays have access to well documented, open sourced TPS to investigate and develop
new methods. A significant amount of time was spent by the author of this work
to develop a software that could be used as a platform for his treatment planning
studies. The result of such effort is PartPlan, a set of scripts developed for the Maltab
computational environment((MATLAB 7.7, The MathWorks Inc., Natick, MA, 2010))
having functionalities similar to what is found in a TPS.
PartPlan reads in CT data in the format used in Virtous software (1). It performs
dose calculations for proton and ion beams based on a Ray-Tracing-WEPL algorithm,
it does treatment plan optimization and RBE-weighted optimization as presented in
this chapter. In addition it calculates the biological effect using precalculated α and β
of the LQ model for a set of pristine Bragg peaks and uses them to get an estimate of
the effect using equations 1.17 and 1.18 1.
1At the moment only data for Human Salivary Gland (HSG) cells is available in the system.
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1Introduction
“It must have occurred to many people that the particles themselves now
become of considerable therapeutic interest.”(8)
The scenario is the post-war America, the year is 1946. Like others brilliant scientist
of his time, Robert Rathbun Wilson belonged to a group of physicist that shared three
things. First, they were part of the generation that followed the golden years of modern
physics. It was a generation that had the enormous task of realizing important tech-
nical and experimental developments after major shifts in paradigms in physics had
taken place just few years ago. Second, he belonged to a selected group of talented
young people who took part in the Manhattan Project. And finally, he was also among
those who, after the war, were very concerned about the military applications of nu-
clear power. In the America of 1946, there were voices already claiming for peaceful
applications of nuclear research.
After the war was over, Wilson accepted a short appointment at the Harvard Cy-
clotron Laboratory. While taking part in the design of the shielding for the cyclotron
he realized that protons could potentially be used as a radiotherapeutic modality and
this idea was published in 1946 under the title ”Radiological use of fast protons”(8).
The idea was so simple and elegant, that in an act of humbleness and modesty, his did
not even attempt to present it as his own:
“It must have occurred to many people that the particles themselves now
become of considerable therapeutic interest. The object of this paper is to
1
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acquaint medical and biological workers with some of the physical properties
and possibilities of such rays.” (8)
Figure 1.1: Depth dose curves for different radiation modalities - Bragg peaks
for carbon ion beams and depth dose curve for x-ray fields is shown. Taken from (9)
This is considered to be the seminal paper for proton therapy and in the America
of the post-war these ideas resonated, they bloomed.
The first patients were treated in physics laboratories. In 1954 the first ion beam
treatments were delivered with protons in Berkeley (10). Three years later proton
treatments began in Uppsala, Sweden (11). During the 60’s and 70’s several research
facilities in Russia and Japan started treatments with protons. In 1961 treatments
began at the Harvard Cyclotron Laboratory in collaboration with the Massachusetts
General Hospital. In 1990 the first hospital based proton therapy facility was built in
Loma Linda University Medical Center (LLUMC) in Loma Linda, California and some
years later the Massachusetts General Hospital opened its fully hospital based proton
program. Nowadays more than a dozen of ion beam facilities for proton and heavy
ion therapy have been built and a good number are either under planning or under
2
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construction. In Germany, the experience from the Pilot Project carried out at the
Gesellschaft fu¨r Schwerionenforschung (GSI) in collaboration with the German Cancer
Research Center (DKFZ) and the University Hospital of Heidelberg led to the creation
of the Heidelberg Ion Beam Therapy Center (HIT) and its currently treating patients
with protons and carbon ion beams. Other facilities in Munich and Berlin offer proton
therapy.
1.1 Dose delivery in ion beam therapy: Active and passive
systems
Generally speaking the machine for ion beam therapy is composed of three main parts.
One part locates the ion sources, the hardware required to inject the particles into
the accelerator and the accelerator itself. This accelerator is either a cyclotron or a
synchrotron. The second part of the system transports the accelerated ions into the
treatment rooms. The last part of the system is is what is used to deliver the beam.
The most important elements for dose delivery are located in this third part. There
are two ways in which the dose can be delivered to the patient, we will refer to them
as active and passive systems.
The passive system is right now the most common modality of dose delivery. Some
of its design was already suggested by Wilson in his seminal paper. He wrote:
“In treating large tumors, for example, one will want to cover the whole
volume with the very high ionization density which obtains over the last
few millimeters. This can easily be accomplished by interposing a rotating
wheel of variable thickness, corresponding to the tumor thickness, between
the source and the patient.”(8)
It is remarkable that in this early paper the use of a modulating wheel is already
proposed. However in order to make a passive system more elements are needed. Very
briefly, the main components of a passive delivery system are:
Scattering device(s) : In order to use ion beams therapeutically they must be
broaden to cover field sizes up to 20-25 cm. For small field sizes such as the
ones used for uveal melanoma irradiations, a single scattering foil is sufficient.
3
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A high density material, like lead, is usually used. For bigger field sizes a dou-
ble scattering system is used. It consist of a set of foils usually referred to as
first scatterer (placed near the nozzle entrance) and a second scatterer usually
gaussian shaped (placed further downstream). A very complete discussion on the
scattering physics and the design of the scattering devices can be found in (12).
Modulator wheel : As suggested by Wilson (8), it is made of set of absorbers of dif-
ferent thickness placed on a wheel. By rotating the wheel each of the absorbers
will meet the beam reducing the range of the monoenergetic particles. By com-
bining the different pristine Bragg peaks obtained with each of the absorbers of
the wheel the Spread Out Bragg Peak (SOBP) is generated. Very often the wheel
is made of a combination of low-Z materials and high-Z materials. The low-Z ma-
terials slow down the particles with minimal scattering while the high-Z materials
spread out the beam at each depth.
Collimators and apertures : They shape the field to the adequate profile. The
material often used is brass.
Compensator : It adjusts the distal part of the dose distribution to conform the
shape of the target. Compensators and apertures are patient and field specific
hardware.
In the passive delivery system the dose is delivered simultaneously to the plane
perpendicular to the direction of the beam at a given depth (thanks to the scatterers)
and within fractions of seconds to the whole volume (by using the modulator wheel).
The active delivery system carefully locates the beam spots one at the time over
the whole target. In order to control the depth (or range) of the particle, the energy of
the beam is adjusted either by the accelerator itself (in the case of the synchrotron) or
by placing a slab of material to slow down the beam (as it is done for cyclotrons). In
order to move the beam spot off the central axis two approaches have been implemented
clinically. At GSI a set of magnets,usually called scanning magnets, allows to locate the
particle at any position in the transversal plane (14). A representation of this design
is show in Figure 1.3. At the Paul Scherrer Institute (PSI) in Switzerland, a wobbler
magnet laterally deflects the particles in directions parallel to the x-z plane (13). The
4
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Figure 1.2: Active delivery system at PSI - Schematic representation of the active
delivery system used at the Paul Scherrer Institute (PSI) in Switzerland. Taken from (13)
Figure 1.3: Active delivery system at HIT/GSI - Schematic representation of the
active delivery system used at Heidelberg Ion Beam Therapy Center in Germany. Taken
from (14)
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location of the spot in the y-component is achieved by moving the treatment table.
Figure 1.2 shows the schematics of the design.
The two systems have different advantages and disadvantages. In the case of passive
systems, these are remarkable robust and stable; commissioning and quality assurance
are much simpler than for active systems and are generally well understood thanks to
more than half of century of use and experience. On the negative side, it requires a
large amount of hardware some of which is specific for each patient and each field. Also
there is a dosimetric disadvantage compared to active systems. The reason is that since
the high dose region of the SOBP is fixed and only the distal edge is possible to shape
(by using the compensator) there is always a high dose region between the entrance and
the proximal edge of the target. This dose however reduces as several fields are used
from different directions. In the case of active systems, they allow for more flexibility in
the planning, which will be discussed in next sections. They do not make use of patient
specific hardware for the delivery and it also offers a lower production of secondary
neutrons in the nozzle. On the negative side, the commissioning as well as the quality
assurance tends to be complicated; the flexibility it offers also demands expertise and
caution and moving targets are a particular challenge for this type of delivery.
1.1.1 Dose Calculation for active delivery systems
The limited configurations in hardware make the dose calculation in water for passive
systems a much simpler problem than for active delivery systems. In his draft paper
Gottschalk (12) gives a profound discussion on the dose calculation and design of passive
delivery systems.
For active systems the calculation of the absorbed dose is done “spot by spot”.
That means that the treatment planning system should be able to model the radiation
transport of quasi-monoenergetic ion beams inside the patient. Broadly speaking, there
are three classes of algorithms that have been suggested and implemented in particle
therapy. These are:
Ray Tracing-WEPL :A ray tracing algorithm calculates the dose deposition along
the central axis of the path of the particle. To account for the effect of scattering
on the dose authors have used an energy dependent gaussian or double gaussian
smoothing as in Kra¨mer (15). To account for heterogeneities the concept of
6
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Water-Equivalent-Path-Lenght (WEPL) is used. The WEPL of a material sample
is defined as the magnitude of the shift of the Bragg peak after the sample is
located in front of the beam as compared to reference measurements.
Figure 1.4: WEPL approach for dose calculation 1 - (a) Schematic representation
of the experimental set up for WEPL measurements. (b) Depth dose curves obtained by
using different absorbers. The shift in the location of the Bragg Peak corresponds to the
WEPL value. Taken from (16)
Pencil beam algorithms : Make use of a precalculated dose kernel in water for each
of the ion beam energies used in a treatment. These kernels take into account
scattering (17). When the dose is calculated in heterogeneous media the dose
is scaled according to the stopping power of the material. In that sense only a
local correction for scattering is employed. A second generation of pencil beam
algorithms was proposed by Szymanowski and Oelfke (18, 19) in which CT data
is used to model the non-local aspect of the scattering effect.
Monte Carlo Methods : Considered by many as the gold standard for radiation
transport simulations, this methods have been used in nozzle design of passive
systems (20, 21). Their clinical implementation in active delivery systems has
7
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Figure 1.5: WEPL approach for dose calculation 2 - Example of a HU-to-WEPL
calibration. Taken from (16)
been reported by Paganetti (22) and Mairani (23). It is expected that as computer
performance increases these methods will begin to have a more active role on daily
clinical usage.
1.1.2 Active delivery system concepts for treatment planning
Having an active delivery system allows for great flexibility in treatment planning.
Various techniques using different complexities of beam spot modulation have been
identified and discussed in the literature (24). These are:
Single Field Uniform Dose (SFUD) : With this technique each field delivers a
uniform dose to the target by adapting the energy of the particles to conform
the proximal and distal edge. It offers an improvement over the dose distribution
obtained with passive delivery systems in that all particles stop inside the target
volume or within few millimeters from it, as opposed to stopping in healthy tissue
located in the proximal region of SOBP.
2.5D Modulation : With this technique the dose is modulated only in the plane
transversal to the beam and not in depth.
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Distal Edge Tracking (DET) : Proposed by Deasy (25), in this technique the beam
spots are located in distal region of the target for each field. The result is that
most of the target volume is irradiated with plateau dose. The technique delivers
perhaps the lowest possible dose to healthy tissue located in the proximal region
of the target for each field. A major disadvantage is the location of the highest
LET component on the edge of the target close where healthy tissue and organs
at risks are often found.
Intensity Modulated Particle Therapy (IMPT) : Although intensity modula-
tion is required in proton therapy to produce even a simple SOBP, the term
IMPT refers to use to nonuniform dose distributions from a number of fields that
add up to a homogeneous dose distribution(24). In the IMPT technique the in-
tensity of every beam spot becomes a free parameter which has to be set. This
is done in a similar way as fluence maps are calculated in the IMRT technique
in photon therapy and it is known as inverse planning. Just like in IMRT, con-
straints to organs at risk can be taken into account. Both SFUD and DET as well
as 2.5D modulation can be seen as special instances of the more general IMPT.
Another technique often found in clinical practice is the so called field-patching.
The technique employs two or more field where each field irradiates uniformly a part of
the target. In some cases this helps to reduce medium and high doses in regions close
to the target as well as it lowers the integral doses.
1.2 The concept of radiobiological effectiveness in Ion Beam
Therapy
Radiation therapy in an empirical discipline. Prescribed doses to the target, to boost
regions, tolerance doses and volumes for organs at risk, integral doses, late and acute
effects of radiation have all been quantified and studied after more than a century of
clinical practice. This clinical practice has been obtained mainly with photon ther-
apy which means that the experience gathered apply for that specific type of radiation
quality. However it has been known for decades that absorbed dose does not determine
uniquely the effect of radiation in cells and tissue. Not just the quantity of the radiation
absorbed but also its quality play an important role in estimating the magnitude of the
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Figure 1.6: The flexibility of the active delivery system - Different techniques
available with an active delivery system. (a) Emulation of a passive delivery system (b)
Distal Edge Tracking technique, (c) 2.5D modulation, (D) 3-D IMPT technique. Taken
from (24)
damage in human cells. When a new radiotherapeutic modality arrives using a differ-
ent type of radiation quality, questions appear: “Which dose should be prescribed?”,
“Which effects can be expected in normal tissue?”.
Early researchers understood that it was hard to get a quantification of radiation
effect in absolute terms for every type of radiation quality. With the years the question
was preformulated: “Which dose Dapplied gives the same effect as Dref Gy of photon
dose?”
The concept of radiobiological effectiveness (RBE) was born out of this question.
The definition is as follows:
RBE =
Dref
Dapplied
|isoeffect (1.1)
That is, the quotient between the reference absorbed dose (usually obtained with
photons) and the dose investigated that give the same issoeffect. In radiotherapy the
problem of RBE is the problem of finding the dose prescription for a defined isoeffect.
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Mathematically this is often stated as:
Dpres = RBE ∗Dapplied (1.2)
The value of the RBE depends among other things on the radiation quality, on
the dose, on the specific endpoint under consideration, on the fractionation, on the
biological system.
For proton therapy the value of the RBE from cell survival experiments as well as in
vivo data has been discussed extensively in (26). A generic value of 1.1 is used in almost
all institutions independent of dose per fraction, proton energy, location in the target
and tissue. To estimate the effects of radiation in proton treatment the absorbed dose
is multiplied by 1.1 and the result is given in units of gray equivalent (GyE)1. This
RBE-weighted dose is used to estimate the effect in the tumor and in normal tissue
using photon dose response data.
The situation is more complicated for carbon ions since the radiation quality changes
dramatically with depth along the depth dose curve. This means that at different
locations in target and organs at risk the quantity and the quality of the energy absorbed
is different and a generic RBE can not be used. Nowadays only three institutions are
treating patients with carbon ions: the HIMAC facility in Chiba, Japan, the HIBMC
facility in Gunma, Japan , and the Heidelberg Ion Therapy Center (HIT) in Heidelberg,
Germany.
The dose prescription in the Japanese institutions is described in (27) goes as fol-
lows:
• For each predefined SOBP, the modulator wheel is designed in such way so that
along the SOBP one measures the same effect on a cell survival experiment. The
biological system used is Human Salivary Grand (HSG) Tumor cells and the
endpoint is 10% survival fraction after irradiation.
• These institutions have had from the past valuable experience with fast neutron
therapy. The dose average Linear Energy Transfer (LET) of the fast neutron
spectrum used is close to 80keVµm . HSG cell experiments with mono energetic
carbon ions having the same LET resulted on the same issoeffect. Because of this
1The unit Gy(RBE) has lately be suggested by the ICRU.
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the depth in a SOBP at which the dose average LET is equal 80keVµm is referred
by them as neutron equivalent position.
• The absolute value of the clinical dose is obtained by multiplying the absorbed
dose at the neutron equivalent position by the clinical RBE known by them from
their experience with fast neutron therapy. The value used is RBEclinical = 3.
The value of the clinical dose is assumed to be constant along the SOBP (thanks
to the constant biological dose for the HSG cells endpoint) so the RBEclinical at
each depth is calculated by dividing the clinical dose by the absorbed dose at
each point along the SOBP.
This prescription is fixed for an specific fractionation schedule and treatment field.
Figure 1.7 shows the idea of the calculation.
Figure 1.7: RBE concepts at NIRS - The dashed line represents the biological dose
with an endpoint of 10% survival in HSG cells. The solid line above represents the clinically
equivalent SOBP. Taken from (27).
The situation is different at HIT in Heidelberg. Having an active delivery system
allows for a very large amount of possible treatment fields each of them with different
radiation qualities. Several models have been suggested to estimate the biological effect
in ion beam therapy. Hawkins proposed a model based on microdosimetric quantities
(29, 30), Wilkens and Oelfke used a phenomenological approach (31) and Scholz and his
collaborators proposed the so-called Local Effect Model (LEM)(32, 33). These models
12
1.3 Inverse planning and optimization
Figure 1.8: From in vitro to in vivo effects - Vertical lines represent the modeling
of the biological effect using the LEM model. Horizontal lines represent the step from in
vitro to in vivo by means of the Linear Quadratic model. The same approach is used to
obtain different fractionation schedules (28).
share in common that (whether by using a functional closed form or a computational
procedure) estimate the dependency of α and β parameters of the Linear quadratic
model on radiation quality to assess the effect of radiation in in vitro experiments. The
step from in vitro to in vivo assessment of the effect is still an open problem. So far
the only model that has been used clinically for an active delivery system is the LEM
model. In the LEM model the step from in vitro to in vivo is made via the alpha beta
ratio of the biological system in consideration, which is extracted from clinical data. An
approach based on the Linear Quadratic model is used. when a fractionation scheme
needs to be designed. Figure 1.8 shows this. A comparison between the model and the
experimental results was published by Karger (34).
1.3 Inverse planning and optimization
One of the most important developments of modern radiation therapy was Intensity
Modulated Radiation Therapy (IMRT). This modality allowed to combine highly mod-
ulated photon fields to better conform the dose to the target volumes. It allowed for
13
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conformal avoidance to reduce the absorbed dose in healthy tissue and organs at risk
(OAR). In order to fully exploit the potential of the technique and to make use of all
the degrees of freedom available a procedure known as inverse planning is used (35).
Inverse planning uses some of the tools of applied mathematics and specially the one
from optimization theory to find the fluence maps needed to achieve a certain goal.
With the arrival of IMPT these tools where also applied for inverse planning in particle
therapy (35, 36).
The description presented below follows Llacer (37) and it shows how the optimiza-
tion algorithm was implemented in the software used in this thesis.
In order to achieve a homogeneous dose Dpres in the PTV Llacer proposed to
maximize the function
K2(~w) =
∑
i∈PTV
[−1
2
ln(2piDi)− (Di −Dpres)
2
2Di
] (1.3)
using an Expectation Maximization algorithm as done by Shepp and Vardi (38) for the
problem of PET image reconstruction. In this formula the vector ~w gives the weight
of the modulation of each beam spot. Di is the dose absorbed in the i
th voxel and it
depends on ~w but this dependency will not always be stated for the sake of clarity.
By using Picard successive approximations he gets:
w
(k+1)
j =
w
(k)
j
qj
{ ∑
i∈PTV
Dij
Dpres
d
(k)
i
}
(1.4)
where
qj =
∑
i∈PTV
Dij (1.5)
d
(k)
i =
∑
j
Dijw
(k)
j (1.6)
w
(k)
j is the k
th iteration of the weight of the jth component of the beam spot mod-
ulation vector, D
(k)
i is the k
th iteration of the value of the dose in the ith voxel and
Dpres is the prescribed dose.
If one wants to take into consideration dose volume histogram constraint (D1, V1)
for the OAR the iterative scheme becomes:
w
(k+1)
j =
w
(k)
j
qj
{ ∑
i∈PTV
Dij
Dpres
d
(k)
i
+
∑
l∈M
βlDlj
D1
d
(k)
l
}
(1.7)
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where
qj =
∑
i∈PTV
Dij +
∑
l∈M
Dlj (1.8)
M =
{
l ∈ OAR | D2 ≥ d(k)l ≥ D1
}
(1.9)
βl is a penalty factor for the l
th voxel of the OAR and D2 is such that:
V1 = DVH(D2) (1.10)
In the case of a maximal dose constraint D1 = Dmax and
M =
{
l ∈ OAR | d(k)l ≥ D1
}
(1.11)
1.3.1 RBE-weigthed dose optimization
For the case of carbon ion treatments is mandatory to take into account the RBE, or
in other words, to prescribed RBE-weighted-dose instead of just absorbed dose. The
problem is then to find a ~w∗ such that:
~w∗ = arg min
w
K1(~w) (1.12)
where
K1(~w) =
∑
i∈PTV
(RBEi(~w)).Di(~w)−Dpres)2 (1.13)
In the previous formula Dpres is the prescribed dose in GyE, Di is the absorbed
dose in the ith voxel and RBEi is the RBE value for that voxel under that specific
beam modulation1.
A problem with this approach is the obvious nonlinearity of the function RBE(~w)
which increases the complexity of the optimization problem to be solved. This com-
plexity can translate into extended calculation times which in a clinical environment
are undesirable.
1Here the endpoint is the one obtained by irradiating the biological system with a Di with a
radiation field having the same quality as the one presented in the voxel
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An alternative to the use of the RBE(~w) function is the optimization based on the
radiobiological effect. Wilkens and Oelfke(39) proposed a particularly fast approach
which will be followed in this work1.
In the linear quadratic model the effect is understood as negative of the logarithm
of the survival function:
E = −ln(S) = αD + βD2 (1.14)
If one thinks of the linear quadratic model as poissonian model for the distribution of
lethal lesions, then the effect would be the mean value of lethal lesions as a function of
the absorbed dose.
If Epres is the effect obtained after applying a dose Dpres and Ei is the effect in the
ith voxel, then the problem can be preformulated to the minimization of the function:
K2(~w) =
∑
i∈PTV
(Ei(~w)− Epres)2 (1.15)
=
∑
i∈PTV
(αi(~w)Di(~w) + βi(~w)D
2
i (~w)− Epres)2 (1.16)
Generally speaking, the quality of the radiation absorbed (often quantified with the
LET or by using microdosimetric quantities) changes from voxel to voxel. It has been
shown that the value of the alpha parameter increases almost linearly with LET until
it reaches a maximum, then decreases. The dependency of beta on LET is still an
open problem but it is expected that this dependency is less pronounced as compared
to the case of alpha. Zeider and Rossi (40) used the Theory of Dual Radiation Action
(41) to estimate the value of the α and β parameters in a mixed field. They proposed
to calculate the alpha by doing a dose weighted average of the alpha values obtained
with the radiation that makes up the mixed field. This method is also used for the
calculation of the square root of beta. Later on Kanai (42) used these relationships
in order to estimate the survival of V79 cells irradiated with carbon ion beams. The
relationships are the following:
α =
∑
k αkDk∑
kDk
(1.17)
1This is the approach implemented in PartPlan for RBE-weighted dose calculation.
16
1.3 Inverse planning and optimization
√
β =
∑
k
√
βkDk∑
kDk
(1.18)
where αk and βk are the ones obtained by irradiating the cell lines with the k
th
component of the radiation field, and Dk is the dose that such component delivered.
In the case of a treatment in a voxelized geometry the alpha value calculated for
the ith voxel would be:
αi =
∑
k αikDik∑
kDik
(1.19)
where αik is the alpha value of the k
th beamlet in the ith voxel and Dik is the dose
delivered to the ith voxel from the kth beamlet under the given beam modulation. Fik
is the dose absorbed in the ith voxel when irradiating the volume with the jth beamspot
(or beamlet) with one particle (or one unit of fluence). The dose Dik is equal Fik times
the number of particles in the beamspot wk.
αiDi =
∑
k
αikFikwk (1.20)
Setting ∆ik = αikFik we get:
αiDi =
∑
k
∆ikwk (1.21)
Similarly for the betas, if we set Ωik =
√
βikFik
βiD
2
i = (
∑
k
Ωikwk)
2 (1.22)
With this formulas the effect based objective function to minimize becomes:
K2(~w) =
∑
i∈PTV
(
∑
k
∆ikwk + (
∑
k
Ωikwk)
2 − Epres)2 (1.23)
Wilkens and Oelfke (39) used a limited memory BFGS algorithm to minimize this
function. Another way to solve this problem is to take advantage of the dominant
behavior of the linear term in high LET radiation by using a similar iterative scheme
as the one shown in the previous section but actualizing the impact of the quadratic
term at each iteration. One can think of it as a quasi-linear approach. The method is
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very fast and uses a limited amount of memory. The desired beam spot modulation is
then:
w
(k+1)
j =
w
(k)
j
qj
{ ∑
i∈PTV
∆ij
Epres
E
(k)
i
}
(1.24)
where
qj =
∑
i∈PTV
∆ij (1.25)
and
E
(k)
i =
∑
j
∆ijw
(k)
j + (
∑
j
Ωijw
(k)
j )
2 (1.26)
Similar strategies to the ones presented in the previous sections can be used to take
into account OAR sparing.
1.4 The challenge of robustness in ion beam treatment
plans
Ion beam treatment plans have been known to be very sensible to errors and uncertain-
ties in the modeling and delivering of the dose. Several types of uncertainties might,
in some situations, compromise the potential benefits of the modality. Some of these
uncertainties are common to all modalities in external radiation therapy like the prob-
lem of inter fraction and intra fraction motions. Others are inherent challenges coming
from the very laws of the interaction of charged particles with matter raising questions
on the precision and accuracy of the dose calculation in a patient. They will be briefly
presented below.
1.4.1 Precision and accuracy of the dose calculation
As described above, there is a wide range of approaches for dose calculation in ion
beam therapy. Different algorithms use different types of data for modeling the energy
deposition in a patient. The precision and accuracy of the dose calculation will generally
speaking depend on two things: the uncertainties of the data used (i.e. stopping
power values or composition of patient’s tissues) and the validity and correctness of
the assumptions of the model.
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Let’s start with the uncertainties of the input data. In a WEPL-based algorithm the
accuracy of the calculation is strongly linked to the errors in the Houndsfield Unit-to-
WEPL calibration. This calibration is purely phenomenological and is likely to induce
a systematic error in the calculation of the WEPL value. As shown in Figure 1.5 there
are important deviations from this calibration for PMMA materials and materials with
high CT numbers. The calibration also fails to give an accurate value of the WEPL
for metal materials due to the obvious problem of obtaining a correct Houndsfield Unit
(HU) value for it. For Monte Carlo and pencil beam algorithms, the values of the
stopping and scattering powers play the crucial role. The task of accurately estimating
the stopping power values in a clinical situation is enormous. Schneider et al (43)
proposed a method to calculate the material composition of each voxel based on CT
data. One could then used the Bethe-Bloch formula to obtain a value of the stopping
power. However one should also take into account that the Bethe-Bloch formula itself
might introduce errors. Of particular interest is the so called I-value for different
materials. It is a matter of intense debate the value of this quantity even for media
such as water. These uncertainties lead to an error in the dose estimation at each
voxel. Another way of looking at the problem is saying that the uncertainties lead to
a range error. This interpretation of the problem is often used since it points out the
magnitude of the problem under consideration: if particles are not stopping where they
are supposed to then the dose absorbed might very heavily deviate, at each point, from
the one prescribed.
Even if the data that each of the dose calculation engines take as input has no errors
there is the question of the validity of the assumptions used in each model. In Ray-
Tracing algorithms scattering of particles is neglected and the effect of such scattering
is approximated by using a gaussian or double gaussian smoothing of the dose obtain
along the ray. In pencil beam algorithms the dose is laterally scaled according to the
value of the stopping powers. As mentioned before, an improvement on this approach
was recently proposed (18, 19) where corrections are made to take into account a
better description of scattering phenomena. Failing to properly describe the scattering
of particles in heterogeneous media leads to dose calculation that could, for instance,
neglect the so called Bragg Peak degradation phenomenon. Bragg peak degradation is
discussed in (44). There is shown that thin inhomogeneities might have strong influence
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on the delivered dose usually deviating significantly from what is expected. A graphical
representation of this phenomenon is shown in Figure 1.9(b).
Figure 1.9: Impact of heterogeneities on the range of particles - Figure (b)
illustrates the Bragg Peak Degradation. Figure (c) shows the effect of a misspositioning
the patient. Taken from (45).
The accuracy of the dose calculation is also connected with the correct modeling of
the patient. Being the CT numbers the main parameter for the characterization of the
physical properties of the voxel its value must be known with low uncertainties. Lomax
(45) has shown that variations of 3% in Houndsfield Units leads to range errors of the
order of 5%, that is 5 mm for every 10 cm in water!.
Recently efforts have been put in order to better describe the physical properties of
each voxel using alternative imaging modalities. Bazalova (46, 47) used Dual Energy
CT to provide a better material segmentation. Hunemohr et al (48, 49) used Dual
Energy CT to provide a better HU-to-WEPL calibration.
Another limiting factor in modeling the patient is the resolution of the voxel ge-
ometry. Specially in regions of high heterogeneities having a voxel sizes that are too
big might lead to an inaccurate assessment of the of the dose calculation failing, for
example, to model Bragg Peak degradation.
The problem of the accuracy of the dose calculation and the impact of errors on
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the dose delivered remains today, despite significant contributions, an open problem.
In clinical practice physicist are encouraged to take special caution when dealing with
this type of problems. As Lomax points out:
“Our analysis seems to imply, of these two problems, range uncertainty
is the most important, as it has a potentially larger effect on the dose
distribution than uncertainty in the dose calculation. However, as the effects
of both uncertainties could very well be systematic over all fractions, we
would advise that particularly complex plans are routinely analyzed taking
such effects into account.”(45)
1.4.2 Intra- and Inter-fraction motions
For interfraction motions we will understand the type of errors induced by the inac-
curate assessment of the position of the relevant structures from fraction to fraction.
The source of these errors can be either a modification in the patient’s anatomy, a
movement of the relevant structures with respect to an internal frame of reference or
a misspositioning of the patient in the treatment table. The later will be also referred
as set-up (SU) error.
To avoid set up errors is a task that every medical physicist working in the clinic
has to face independent of the modality of external radiation therapy. With the arrival
of Image Guided Radiation Therapy (IGRT) tools have been found to address this
problem, or at least, to fully known its extension. The situation is potentially more
dangerous in ion beam therapy than in photon therapy since a misspositioning of just
few millimeters might lead to the incorrect placement of beam spots. This situation is
shown in Figure 1.9(c).
The impact of set up errors on ion beam plans has been studied by Lomax (50)
in the case of proton therapy and Karger et al (51) for Carbon Ion Therapy. Karger
analyzed the effect of set up errors on plans of cervical spine tumors for both IMRT
and carbon ion therapy with an active delivery system. He concluded that carbon ion
therapy is more sensible to set-up errors that IMRT. For the particular case of cervical
spine tumors he observed a larger deviation for carbon ion therapy in the dose measured
in the organ at risk as compared to IMRT.
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Lomax on the other hand has shown the importance of imaging prior to dose delivery
for each fraction. He showed that although misspositioning errors can correspond to
histograms with arbitrary shapes, if one repositions the patient using IGRT based
imaging techniques the residual error in the position can be well approximated by a
bell shaped probability density function (in each of the three dimensions) having an
average value of zero and a standard deviation below 1.5 mm. That is probably as good
as it gets for dealing with this kind of uncertainties. They cannot be fully eliminated
from the treatments and one could only hope to reduced them to a minimal expression,
characterize them and take countermeasures to compensate for the impact they might
have in the treatment.
Intrafraction motions will be understood as the movements occurred during the
delivery of the dose. This problem is often known as the organ motion problem. The
problem of organ motion has been studied by Bert (52, 53, 54), Furukawa (55) and
Kraus (56) in the context of ion beam therapy with active delivery systems. The
interference of the scanning pattern and the motion of the organ produces a dose
distribution that is, usually, heavily deteriorated and its known as interplay effect The
problem is more severe as the number of fractions decreases.
In order to reduce interplay effect, three mitigation techniques have been proposed:
rescanning, gating and tracking. In the rescanning technique the delivery of the dose
in each beam spot is not done at once but it is divided into several instances. The idea
behind is that organ motion will have a different effect in each instance averaging out
the dose delivered to each spot. Gating is a technique used in other types of external
radiation therapy. The idea behind gating is to a priori characterize the movement of
the organ and deliver the dose in the time phase in which the movement is minimal.
It often assumes that the organ moves in constant, periodic motion. Finally, tracking
aims to take into account the movement of the target and “paint it as it moves”. In
involves fast adaptation of the treatment parameters as the organ moves.
The potential use in clinical practice of these mitigations strategies is being inves-
tigated and studied (52, 53, 54, 55, 56) as right now this is one of the aspects limiting
the applicability of the active delivery system.
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“In addition, for proton therapy using spot scanning, as performed at our
institute, collimation and compensation are not used, meaning that the traditional
methods of dealing with uncertainties cannot be adopted. For this reason, we
nevertheless currently manage delivery uncertainties using the PTV concept as in
conventional therapy.”(50)
Prof. Dr. Wolfgang Schlegel from the German Cancer Research Center (DKFZ) and
the University of Heidelberg usually refers to radiation therapy as the art of hitting
a target we do not see with an invisible beam. The sentence, simple and rhetorical,
embraces one of the fundamental challenges of dose delivery in radiation oncology. As
discussed in Chapter 1, several sources of errors have made the problem of dose delivery
difficult. Some of these are: the motion of the tumor due to physiological processes, the
miss-positioning of the patient prior to delivery, the movements of the patient during
the treatment, the changes in the tumor volume and shape as well as the changes in
the anatomy of the patient as a result of the treatment.
Clinicians early realized that something was needed in order to take care of the
effects of errors and uncertainties present in the delivery of radiation. The first step
was, obviously, to try to minimize the value of these errors. This led to the development
of immobilization devices, treatment simulators and positioning systems which can
be found in hospitals today. The second step established a framework that aimed
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to guarantee the correct dose delivery in the presence of (the previously minimized)
uncertainties. The idea was to make sure that the dose delivered to the tumor deviates
only slightly from what is prescribed. It was an issue of robustness. In the heart of this
framework lay the concepts of Target Volumes. In the next sections these concepts will
be explained as they are proposed in the ICRU 50, 60 and 78 (57, 58, 59) and later in
the chapter it will be shown how they are inappropriate for Ion Beam Therapy. Then
Dynamic Target Definition will be introduced as a way to update the concept of Target
Definition for proton and ion beam therapy.
2.1 Target Volume Definitions
2.1.1 Gross Tumor Volume
The Gross Tumor Volume (GTV) is the macroscopic malignant mass that can be iden-
tified by the use of different imaging techniques. Its determination and size depends
mainly on two factors: the imaging modalities used and the subjective experience of
the clinician. X-rays were often used in the past for such determination. With the
development of new types of imaging it is now possible to use transmission computer
tomography (CT), positron emission tomography (PET), single particle emission to-
mography (SPECT), nuclear magnetic resonance (MRI) and ultrasound. Having dif-
ferent imaging modalities makes it possible to have quantitative information of the
anatomy and physiological processes in a given region of the patient allowing to make
a clearer distinction between what is malignant and what is not.
2.1.2 Clinical Target Volume
Since all imaging modalities have limited resolution there will always be malignant cells
that will not be identified as a part of the GTV. The Clinical Target Volume (CTV) is
the expansion of the GTV that aims to include those tumor cells. It is the fundamental
volume, the clinical statement of what is needed to be treated. Its determination occurs
prior to the selection of treatment modality or technique used.
The CTV is usually created by expanding the GTV by margin. Depending on the type
of tumor and its location the size of the margin will be different. Clinical experience
based on the history of local recurrence for patients with the same type of tumor plays
a fundamental role.
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2.1.3 Internal Target Volume
The Internal Target Volume (ITV) is an expansion of the CTV by a so-called Internal
Margin (IM). The value of this margin is given by the variations in shape, size and
position of the CTV with respect to an internal frame of reference. The main motivation
for this structure is to take into account the changes in the position and the shape of
the CTV due to anatomical changes in the patient during the course of a treatment
or during the course of a fraction. A good example is the motion of the CTV in lung
cancer patient due to breathing. The concept was introduced in the ICRU 62 (58) in
a moment when IGRT was ad portas of worldwide clinical implementation.
2.1.4 Planning Target Volume
Each treatment modality has intrinsic inaccuracies and errors that challenge the deliv-
ery of the dose to the CTV. The Planning Target Volume (PTV) is an expansion of
the ITV (or the CTV, if the ITV is neglected) that aims to take into account all the
net effects of all the geometrical variations and inaccuracies so that the CTV receives
the prescribed dose. Some examples of the kind of errors that the PTV concept aims
to mitigate are:
• the miss-positioning of the patient in the treatment room prior to delivery.
• mechanical uncertainties of the equipment
• dosimetric uncertainties
It is worth mentioning that the size of the beam has to adjusted so that the width of
the penumbra falls outside of the PTV. The size of the PTV volume is then a geometric
construction dependent on the degree of uncertainties of a specific modality and delivery
technique in a given institution.
Although the idea of volume expansions might be straightforward to understand,
the size of the margins itself is not trivial and it is a topic on intense debate in the
literature (60, 61, 62). Figure 2.2 shows different margin recipes taken from different
authors.
25
2. THE PROBLEM OF PTV DEFINITION IN ION BEAM THERAPY
Figure 2.1: Volume concepts in Radiation Therapy - taken from (62)
2.1.5 Additional Volumes
Other structures are defined in the ICRU 50 and 62(57, 58), some of which are important
for the discussion in the next sections. They are:
The Treated Volume (TV): The volume receiving a dose equal or larger than 95%
of the prescribed dose.
The Irradiated Volume: The volume of tissue receiving a dose that is significant
compared to the tolerance of the normal tissue.
The Organs at Risk (OAR): Organs or volumes of tissue whose function might be
affected given their intrinsic radio-sensitivity.
The Planning Organs at Risk Volumes (PRV): An expansion of the OAR by an
internal margin and a set-up margin. It is an analogous expansion as the one done
from the CTV to the PTV. The idea behind the PRV is to make sure that the dose
absorbed in OAR are below the threshold, even in the presence of uncertainties.
The volumes described above are shown in Figure 2.1.
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Figure 2.2: Brief summary of Margin Recipes - taken from (61)
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2.1.6 Conformal Avoidance and Conformity Index
During the last two decades of the 20th century radiotherapy lived a technological
revolution. The incorporation of computers in clinical practice brought not only the
advances in imaging and information management to the radiation therapy departments
but also, together with invention of the Multileaf collimator (MLC), gave rise to the
automatization of the so-called 3-D Conformal Radiation Therapy (3DCRT) and later
the well known Intensity Modulated Radiation Therapy (IMRT). These two techniques
of conformal radiation therapy allow to spare the normal tissue and OARs reducing the
severity of complications associated with radiation therapy. This is know as conformal
avoidance and it was the main motivation for the development of this type of technique.
It has been stated that a homogeneous dose distribution to the PTV is desirable
(57, 58). Since this requirement is in practice very difficult to achieve the ICRU 62
(58) recommends not to allow the deviations of the values of the dose fall below 95%
or go beyond 107% of the prescribed dose. The same report introduces a measure of
conformity called the conformity index (CI) defined as the size of the treated volume
divided by the size of the PTV:
CI =
Size of the TV
Size of the PTV
≥ 1 while PTV ⊆ TV (2.1)
Following the recommendations, the value of CI should be as close to one as the
technique allows it to be.
2.1.7 Static Dose Cloud Approximation
If one tries to deal with uncertainties by using volumes expansions like the one made
from CTV to PTV a subtle assumption is being made. The dose distribution is then
treated as a rigid three dimensional object whose values are not affected by these
uncertainties, but only its position in a external frame of reference. The idea is that
if the PTV is large enough, the CTV would swim in a pool of therapeutic dose. This
assumption is sometimes referred as the Static Dose Cloud Approximation (63). In
principle the assumption is incorrect. It has been reported (64, 65) that for photon
therapy changes in the dose values up to 5% can been seen in the dose distribution.
There are reasons however why to hold on this assumption. First, the assessment of
the impact of uncertainties on detailed radiation transport in a patient is by no means
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trivial. In fact, it can be regarded as an open problem. Second, if the variation of the
dose in each voxel is no higher than 5% then the error introduced in the approximation
is in the order of magnitude of the error in the measurement of the dose in water. The
approximation seems then reasonable, for photon therapy.
2.2 The problem of PTV definition in Ion Beam Therapy
As discussed above, the main assumption holding the PTV concept is the validity
of the static dose cloud approximation and the isotropic impact of uncertainties on the
delivered dose. For Proton and Ion Beam therapy to benefit from these concepts one
has to make sure that the mentioned assumptions are still valid for this type of therapy.
As a starting point let’s see if, in general, the static dose cloud approximation seems
reasonable. Figure 2.3 shows the ideal locations of beam spots for a simulated treat-
ment of proton therapy with an active delivery system. In this case the beam is being
delivered through the nose. The green volume can be regarded as the PTV and the
red volume represents an OAR. Now lets assume that a small misalignment of 2 mm
in the left-right direction is made while positioning the patient. Figure 2.4 shows the
locations of the beam spot under the unwanted miss-positioning1. Once can see that
distortion in the configuration of the beam spots arrangement is enormous. The mag-
nitude of the displacements is not the same for all beams spots, neither its direction.
It is not difficult to conclude that the overall distortion of the dose distribution is by
more complex than just a “three dimensional shift”.
In clinical practice beam arrangements that go through regions of complex het-
erogeneities are usually avoided. The previous example shows that a small error in
miss-positioning can have a serious effect on the location of the beam spots. Another
reason to avoid lateral interfaces is the challenge that they brings to the accuracy of the
dose calculation. As mentioned in Chapter 1, most algorithms used for dose calculation
make simplifying assumptions on the transport of particles and its derived quantities,
like the absorbed dose. Often used algorithms, like ray tracing algorithms or simplified
pencil beam algorithms are inaccurate in these kind of conditions.
Whether the beam angle makes the treatment extremely sensible to set up errors
1These are calculated using a ray tracing-WEPL approach. The estimation of the location of the
beam spots depends on the type of dose calculation used
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Figure 2.3: Assumed beam spot locations - Contour in green represents the PTV
the and in red an OAR. Arrows are beam spot locations.
Figure 2.4: Beam spot location after an error in positioning of 2 mm - Contour
in green represents the PTV the and in red an OAR. Arrows are beam spot locations.
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or whether the accuracy of the dose engine is challenged by complex heterogeneous ge-
ometries, a volume expansion does not help to mitigate the effect of these uncertainties.
The reason is simple: the static dose cloud approximation, in general, does not hold in
particle therapy.
The isotropic impact of uncertainties on the delivered dose is also challenged in
particle therapy. The reason is that there is an additional source of uncertainty in
this type of modality: the value of the stopping powers (SP) or its related quantity,
the Water Equivalent Path Length (WEPL) of the materials inside the patient. This
uncertainty translates into an uncertainty in the range of the particles. To illustrate
the problem consider the following example:
Figure 2.5 shows a cylindrical phantom consisting of three materials: an outter ring
made out of bone tissue, an inner ring made out of lung tissue and an spherical tumor
made of water equivalent materials.
Structure Material Relative WEPL WEPL Uncertainty
Outter ring Bone tissue 1.6 10%
Inner ring Lung tissue 0.3 20%
Spherical tumor Water equivalent tissue 1 5%
Table 2.1: Relative WEPL and uncertainties of materials in Figure 2.5.
Table 2.1 shows the values of the WEPL relative to water used for this example.
Let’s also assume that we have assessed the relative uncertainty of this values and that
they are as shown in Table 2.1. These values are not necessarily the ones used in clinical
practice and the uncertainties shown reflect in a pessimistic way a worst case scenario
useful for this discussion. What is important to consider is that:
• The uncertainty of different types of tissue is in general, different.
• Tissues that are close to water equivalence show a reduced uncertainty often lower
than 5%.
• The accuracy of the assessment of the WEPL is reduced for materials with large
or very low values of Houndsfield Units (HU).
Let’s also assume that there is one and only one source of uncertainty to consider: the
WEPL values. In this idealized case no other type of uncertainty will have an effect.
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Figure 2.5 shows the isodoses for a one beam proton plan using a SFUD technique. A
constant RBE of 1.1 will be used here.
Notice that in Figure 2.5 the PTV is the exact same volume as the CTV. That
would be appropriate if no uncertainties were needed to be taken into account. How
will the lack of a margin affect the robustness of the treatment towards CTV dose
coverage? In order to answer this question let’s proceed in the following way:
Figure 2.5: Idealized case for the study of stopping power uncertainties - 100%
isodoses shown in red, 90% isodoses shown in orange, 40% isodoses shown in green and
10% isodoses shown in blue.
1. Calculate the energies and beam spot weights necessary to achieve a homogeneous
dose delivery in the CTV. This is the nominal plan. Store these values.
2. Following a bayesian approach represent the uncertainty of the WEPL values
using a probability density function (pdf).
3. For each material, sample a new instance of the WEPL values from the pdf’s
obtained in the previous step and assign these WEPL values to the materials of
the phantom. In other words: create a new instance of the patient.
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4. Perform a forward calculation using the energies and weights calculated in step
1. Store the resulting dose distribution.
5. Go to step 3 and repeat until a predefined number of dose distributions Nmax has
been collected.
Figure 2.6: Uncertainty of the dose calculation - Standard deviation of the dose
values for each voxel in percent of prescribed dose.
For each voxel we have now a histogram of Nmax realizations of dose values. The
uncertainties of the WEPL have propagated into an uncertainty on the dose for each
voxel. If the uncertainty of the WEPL has an impact of dose coverage on the CTV one
should be able to find voxels having a histogram that
• have a large dispersion of dose values and/or
• have an average value that differs significantly from the prescribed dose.
Those voxels that result unaffected by uncertainties will be refereed as safely treated.
Figure 2.7 shows in red those voxels which are safely treated. The black contour is the
CTV. The following considerations were taken while calculating them:
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Figure 2.7: Impact of the WEPL uncertainties in CTV coverage - Red voxels are
considered safely treated; the black line determines the CTV
Figure 2.8: Impact of the WEPL uncertainties in CTV coverage after applying
a margin - Red voxels are considered safely treated; the black line determines the CTV;
the volume treated was an expansion of 5 mm.
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• As a measure of dispersion, the standard deviation was calculated. A voxel having
a histogram with a dispersion larger that 3% was not considered to be safely
treated.
• A voxel having a histogram with an average value deviating by more of 5% from
the prescribed dose was not considered to be safely treated.
• The WEPL values were sample from rectangular (uniform) probability density
functions having a variance according with the uncertainty values given in Table
2.1.
• A number of Nmax = 100 samples were done.
In Figure 2.7 can be seen that, in fact, some of the voxels of the CTV are not safely
treated. Not surprisingly, those voxels located in the distal part of the beam resulted
more affected by the range uncertainty than those in the lateral part of the beam.
Figure 2.6 shows the values of the standard deviation of the histograms for each voxel.
Figure 2.8 shows the result of the procedure of histogram generation and uncertainty
propagation to a PTV that is a 5 mm expansion of the CTV. We can see that the
problem of robust dose coverage is not solve by applying a 5 mm margin. This concern
is well expressed by Gotein:
“Protons require margins in depth to take range uncertainties into account,
as well as the more traditional lateral uncertainties. At present, these mar-
gins are often quite substantial, especially in the lung whose low density
results in the physical extent of the depth overshoot being some four to five
times greater than would be the case in, say, muscle. A combination of
technical, imaging, and procedural advances need to be developed to reduce
this problem to an acceptable level” (66)
We can then state that for Ion Beam Therapy:
• In general terms, the static dose cloud approximation does not hold.
• The impact of uncertainties (specially those that propagate into range uncertain-
ties) is non-isotropic.
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• Any expansion should take into account beam arrangements and probably beam
spot modulations.
• Adding arbitrarily margins by using margin recipes as way to deal with uncer-
tainties can lead to PTVs that are extremely large.
2.3 Dynamic Target Definition in Ion Beam Therapy
As it was mentioned in the previous section the PTV in Ion Beam Therapy is often
obtained by adding distal and non-distal (lateral and proximal) margins. The value of
the distal margins is calculated on the basis of the range uncertainty (59). However the
range uncertainty, as well as any other type of uncertainty, is important to be taken
into account simply because it has the property of being able to propagate into an
uncertainty in the dose delivered1. The value of the margin should not be dictated by
the range uncertainty (nor the set-up uncertainty or the tumor motion) but by the value
of the dose uncertainty. Any useful margin recipe should minimize the dose uncertainty
in the CTV while keeping the Treated Volume as small as possible.
Looking at Figure 2.7 one can see that set of voxels safely treated make and almost
compact subset of the CTV. The reason why (for this case) the subset is not entirely
compact is that some of these voxels miss at least one of the conditions to be considered
safely treated. However it is important to realize that the values of the standard
deviations and the fluctuation for the mean have an inherent uncertainty depending
on how large is the population of the histogram. To avoid this ” statistical artifact“
one can either increase the number of dose calculations and/or one could apply a
smoothing operation to the set of voxels safely treated. The important thing to notice
is the existence of a quasi-compact subvolume of voxels safely treated.
Having this in mind let’s build on some of the concepts introduced on the previous
section. Let’s define:
tCTV(m,v) : The compact subvolume of CTV voxels that are safely treated, under the
assumption that a voxel is safely treated if the standard deviation of the histogram
generated is lower than v and the average value of the histogram generated differs
1In general to an uncertainty in the delivered RBE-weighted-dose
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from the prescribed dose by at most m. Both values given in percentage of the
prescribed dose.
PTV(m,v) : The compact volume to which the prescribed dose is planned and
delivered. The relation between tCTV(m,v) and PTV(m,v) is such that the
tCTV(m,v) is the compactification of the CTV voxels that were safely treated
when the prescribed dose was plan on PTV(m,v).
The task is now to find the PTV such that for given values m and v,
tCTV (m, v) = CTV (2.2)
Figure 2.9: PTV(m,v) construction - Relevant volumes for the construction of the
proposed CTV expansion
To find such PTV we propose an iterative construction of the volume:
1. Denote Lr the distance from a point of the tCTV to the CTV in the direction
normal to the tCTV surface.
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2. Along that direction move a distance Lb from the border of the CTV. If the point
of the tCTV is outside the CTV then move in the anti-parallel direction (towards
the CTV). Lb will be calculated from the relationship:
Lb
Lr
=
average WEPL of the CTV
average WEPL outside the CTV
(2.3)
where by ’outside’ is meant the close surroundings of the CTV in the direction of
Lb.
3. The point reached is a point of the contour of the PTV(m,v).
4. Plan for uniform coverage of the obtained PTV(m,v). Using this volume, create
a new dose histogram and assess a new tCTV(m,v).
5. Iterate until tCTV(m,v)=CTV.
Figure 2.10: PTV(m=5%,v=3%) - PTV derived using the proposed approach for the
case shown in Figure 2.5
Figure 2.10 shows the obtained PTV(m=5%, v=3%) after two iterations. Figures
2.11 and 2.12 show the tCVTs after one and two iterations respectively.
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Figure 2.11: tCTV(m=5%, v=3%) - First iteration for the case shown in Figure 2.5
Figure 2.12: tCTV(m=5%, v=3% - Second iteration for the case shown in Figure 2.5
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The volume generated (Figure 2.10) is smaller than the isotropic 5 mm expansion
(Figure 2.8). This fact can be seen in the Dose Volume Histogram (DVH) shown in
Figure 2.13, where the dose in the respective PTVs and the integral doses are plotted.
It can also be seen in Figures 2.11 and 2.12 that dose coverage in the CTV (in the
presence of uncertainty) has been improved as compared to Figure 2.8.
Figure 2.13: PTV and Integral doses - Solid lines represent the 5 mm isotropic margin
expansion scenario. Dashed lines represent are for the volumes obtained with proposed
method. Although the PTV coverage seems to be adequate for both expansions Figure 2.8
and 2.12 show how different the mitigation of the error really is.
2.3.1 A Head and Neck case
The results of the previous section motivated the application of the method to a two
dimensional Head and Neck (H&N) case. To make the study more faithful to the
situation found in clinical practice let’s not only take into account the range uncertainty
coming from an inaccurate assessment of the WEPL values but also let’s take into
account the uncertainty introduced by (miss)positioning the patient in a fractionated
treatment. A single field uniform dose technique (SFUD) was used.
The estimation of the WEPL values will be done using a HU-to-WEPL calibration
taken from (16). The quantification of the uncertainty of the WEPL value will be done
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in the following way:
• Voxels having a HU value lower than -300 will be assigned a relative uncertainty
of 20%.
• Voxels having a HU value higher than 700 will be assigned a relative uncertainty
of 10%.
• For the remaining voxels a relative uncertainty of 5% will be assigned.
It is up to the user of the methodology described here to set the values of the WEPL
uncertainties1.
The values used here might seem large but is worth noticing that by using a large
uncertainty we are taking a worst case scenario approach and by doing so, we are putting
ourselves on the safe side 2. Also it is important to remember that even if the HU-to-
WEPL calibration results in a perfect fit with a theoretically established background
there would still be an error induced by treating different tissues as having the exact
same composition (water equivalent). It is then evident than in the assessment of the
absorbed dose using a HU-to-WEPL calibration a number of random and systematic
errors are being induced3. The quantification of these errors by a probability density
function is the heart of the bayesian approach taken here.
For the miss-positioning errors in a multifractionated treatment of proton therapy
Lomax (67) shows that by using alignment techniques common in IGRT they are well
described by a bell shaped probability density function centered around zero. For
this case two zero centered gaussian functions will be used to model the offset of the
patient: One with a σ = 2 mm in the Left-Right (LR) direction and another one with
σ = 1 mm in the Anterior-Posterior (AP) direction. This choice is arbitrary. In clinical
practice the values of these uncertainties should be assessed by the medical physicist.
Inspired in the previous section the uncertainty propagation is performed by doing:
1. Calculation of the nominal plan: Calculate the energies and beam spot weights
necessary to achieve a homogeneous dose delivery in the PTV4. Store these val-
1If the dose calculation algorithm uses the stopping power of the material instead of the WEPL,
then an uncertainty should be assigned to it.
2In an informal way we could say that we are applying a margin to the uncertainty rather than to
the volume. Only in extreme cases, the use of very large uncertainties might lead to very larges PTVs.
3The calibration used here is purely phenomenological
4For both beams simultaneously.
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ues. In the first dose histogram creation any initial guess for the PTV can be
used. Here PTV = CTV was used1.
2a. Representation of uncertainties: Represent all the uncertainties to be taken
into account with probability density functions. In this case they will be: The
uncertainty in the range coming from an inaccurate calculation of the energy
deposited in matter per unit path length (by using the WEPL approach) and the
uncertainty in the positioning of the patient.
2b. Representation of uncertainties: To each voxel assign a new WEPL value by
sampling from the assigned pdf’s. One instance of the sampled error is used for
all the voxels having a HU value below -300. Another instance to those having a
HU value greater than 700 and another instance for HU values in between -300
and 700. The mean value of the pdf is set to be the nominal value give in the
HU-to-WEPL calibration. The variance of the pdf will be chosen in a way that
represents the degree of belief in the dose calculation. For the cases presented
in this section and the following a rectangular (uniform) pdf will be used. The
width of the rectangular pdf should be in accordance with the value of the relative
uncertainties discussed above.
2c. Representation of uncertainties: The value of the shift of the patient form its
ideal position (misalignment) will be sampled from the double gaussian discussed
above.
3. Uncertainty propagation: Perform a forward calculation using the energies and
weights calculated in step 1. Store the resulting dose distribution.
4. Dose histogram construction: Go to step 2a and repeat until a predefined
number of dose distributions Nmax has been collected. For the following cases
a value of Nmax = 100 was used.
The method was applied to the Head and Neck case shown in Figure 2.14. The
method was used for the construction of the PTV in two different plans: a plan using
two horizontal opposing beams and a plan using two oblique beams with angles of 60◦
1Based on the experience gained by practice a physicist could use better initial guesses. This would
reduce the number of iterations necessary to construct the final PTV.
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Figure 2.14: Head and Neck case - Volume expansions with the proposed approach
(A)(B)(E)(F); and with a 5 mm margin (C)(D). Figures (A)(C)(E) are for an oblique
irradiation and Figures (B)(D)(F) for a horizontal (two opposing beams) irradiation. Con-
tours in red correspond to PTVs and contours in green correspond to CTVs. In Figure
(C)(D)(E)(F) voxels in red are considered to be safely treated under m=5 and v=3.
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and 300◦ . Figure 2.14 shows the obtained PTV(5,3) and the tCTVs(5,3) resulting from
such PTVs. For comparison it also shows the obtained tCTVs(5,3) after planning on a
5 mm isotropic margin expanded PTV. In all the cases the results are for one iteration
(one histogram generation) and to the shown tCTVs no compactification operations
were applied.
Figure 2.15 shows the mean dose distribution and uncertainty dose distributions
both normalized to the prescribed dose.
One can see that:
• Beam direction has an effect on the robustness of a plan. Even with an isotropic
expansion the percentage of CTV voxels being safely treated changes considerably
with the beam arrangement.
• The approach presented here produces planning target volumes that change dy-
namically in size and shape with beam orientations. This should not be a surprise
since in the dose calculation engine range uncertainties are dependent on the HU
values that the beam has to go trough and miss-positioning errors, seen as move-
ments, have a larger component in some directions than other.
• The approach presented here enhances the percentage of CTV voxels safely cov-
ered as compared to the isotropic expansion.
• Under the presented method, the most robust beam arrangement will produce a
smaller PTV expansion. This result is logical. The tCTV volume of non-robust
beam arrangements will be smaller than the tCTV of robust beam arrangements.
This means that there is a one-to-one relationship between the robustness of a
plan coming from its beam arrangement and the PTV size generated with the
method.
Table 2.3 shows these features:
2.3.2 A Prostate case
The method was also applied to a two dimensional prostate case. The sources of
uncertainties and their modeling are the same as in the previous case. Again, two
beam arrangements were used. One with two horizontal (opposing) fields and one with
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Plan # Type of expansion Beam arrangement PTV size (in voxels) % of CTV safely covered
1 5 mm margin Horizontal 1004 90
2 5 mm margin Oblique 1004 83
3 Proposed method Horizontal 1140 95
4 Proposed method Oblique 909 98
Table 2.2: PTV sizes and percentage of CTV safely for the H&N case, treated from
volumes in Figure 2.14.
Figure 2.15: Head and Neck case - Mean dose distributions and uncertainties for
Plans #2 and #4 shown in Figure 2.14
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an oblique set of beams (45◦ and 315◦ ). For comparisons the results are also presented
for the case of a PTV obtained by applying a 6 mm constant margin to the CTV,
so a total of four plans were calculated. In every plan a SFUD technique was used.
Figure 2.16 shows these results. Results with the proposed approach are shown for one
iteration.
As in the previous case we can see that different beam arrangements were affected
to a different extent by uncertainties. The PTVs generated with the proposed method
produced different beam expansion depending on the beam configuration used. For both
beam configurations the number of CTV safely covered was enhanced as compared with
number of voxels safely treated with the use of a constant margin. Once again, the
most robust plan had also the smallest PTV (Plan # 8).
Plan # Type of expansion Beam arrangement PTV size (in voxels) % of CTV safely covered
5 6 mm margin Horizontal 1451 84
6 6 mm margin Oblique 1451 64
7 Proposed method Horizontal 1352 90
8 Proposed method Oblique 1312 99
Table 2.3: PTV sizes and percentage of CTV safely for the prostate case, treated from
volumes in Figure 2.16.
Due to the fact that the volume expansion generated with the proposed method
changes with some of the parameters of the plan, such beam angle arrangement and
beam spots modulation1, the target expansion proposed will be referred to as Dynamic
Target Definition (DTD).
2.3.3 Robust conformity indexes
Having explained the idea behind Dynamic Target Definition let’s revisit for a moment
the concept of the conformity index. The conformity index as a quantifier of conformal
dose coverage to the PTV was motivated with the arrival of 3DCRT and IMRT in
photon therapy. As it was discussed earlier, this modalities are less sensible to errors
and uncertainties than ion beam therapy. The question is: just as the standard way
of generating a PTV2 might not be adequate in Ion Beam Therapy, is the notion of
conformity as we know it also adequate? It is said that proton and ion beam therapy
1This will be discussed in next sections.
2As reported in the ICRU 50 and 62(57, 58).
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Figure 2.16: Prostate case - Volume expansions with the proposed approach
(A)(B)(E)(F); and with a 6 mm margin (C)(D). Figures (A)(C)(E) are for an oblique
irradiation and Figures (B)(D)(F) for a horizontal (two opposing beams) irradiation. Con-
tours in green correspond to PTVs and contours in red correspond to CTVs. In Figures
(C)(D)(E)(F) voxels in red are considered to be safely treated under m=5 and v=3. In
Figures (A)(B) the dose uncertainty distribution is shown.
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are highly conformal modalities. Decades ago, no other type of external radiation
therapy was matching the ability to tailor a volume with high dose regions1. Nowadays,
highly conformal therapies are achievable using photons. The question however is not
just about how conformal a dose distribution appears to be in a Treatment Planning
System. The question is: how much can the dose distribution estimated by the TPS
be trusted? To what extent what we see is what we get?. How conformal is the dose
distribution in the presence of uncertainties? How robust is the conformity?
To answer these questions in a quantitative way let’s define the following: The
volume M consisting in those voxels safely treated that belong to the PTV(m,v) but
not to the CTV:
M(m, v) = PTV (m, v) \ CTV (2.4)
The fraction of CTV voxels that are safely treated:
R =
Size of the tCTV(m,v)
Size of the CTV
≤ 1 (2.5)
The number of voxels safely treated that belong to the PTV(m,v) but do not belong
to the CTV. This number is normalized to the number of voxels of the CTV:
C =
Size of the M(m,v)
Size of the CTV
≥ 0 (2.6)
Ideally one would like uncertainties to not affect significantly the dose coverage of
the CTV. That means, a tCTV as close to the CTV as possible. This is the basis
of the idea of robustness towards CTV coverage that motivated the concept of target
expansion and it is quantified by the R value in Equation 2.5. This value ranges from
0 to 1, being 1 the optimal value.
At the same time, it is desirable that the volume of voxels safely treated does not
expand beyond the CTV. Although it is always the case that the treated volume is
larger than the CTV, the reason for an expansion is not to ensure robust coverage
outside of the CTV. For this reason a C value close to 0 is the optimal value. Table
2.4 summarizes the values of CI, R and C for the eight cases shown above.
1In modern photon therapy however the level of conformity is comparable to the one obtained in
ion beam therapy
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Plan # Type of expansion CI R Index C Index
1 5 mm margin 1.11 0.90 0.00
2 5 mm margin 1.11 0.83 0.00
3 Proposed approach 1.09 0.95 0.00
4 Proposed approach 1.14 0.98 0.00
5 6 mm margin 1.06 0.84 0.23
6 6 mm margin 1.06 0.64 0.10
7 Proposed approach 1.10 0.90 0.00
8 Proposed approach 1.12 0.99 0.00
Table 2.4: Comparison of the CI, R and C values for the H&N and the prostate case.
One can be seen that R values obtained by isotropic expansions are the lowest. In
the prostate case, the C values were non-zero meaning that not only the CTV coverage
might have been compromised but that also an unnecessary large volume of healthy
tissue was irradiated with a large dose.
Table 2.4 shows how the values of CI are particularly similar in all the plans studied.
It also shows that the conformity index CI is not a good quantifier of the robustness
of the conformity. The robustness of the conformity can be very well characterized by
the R and S values. It is worth noticing how for Plan # 4 and Plan # 8 the value
of R and C are nearly optimal. In this work this feature will be referred as robust
conformity and the indexes R and C, as their quantifiers, will be referred as Robust
Conformity Indexes.
2.3.4 What about IMPT?
In the cases shown above the treatment modality was proton therapy with an active
scanning delivery system. The technique used was SFUD. A natural question then
arises: What about IMPT?
Let’s apply the DTD to two different IMPT plans: oblique plan an opposing field
beam plan. Figures 2.17 show the results of a modulated prostate plan with the oblique
(45◦ and 315◦ ) beam arrangement and Figure 2.18 shows the results for the horizontal
beam plan. The sources of uncertainties used and their values remained the same as in
previous section. Figure 2.18 shows a nice and compact tCTV volume generated. The
existence of such volume is the heart of the DTD method and the rationale of the PTV
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concept. However Figures 2.19 and 2.20 show a very different type of result. Under
this specific IMPT plan protons are stopping near the center of the CTV. This leads
to high uncertainty regions inside the CTV as opposed to having them in the distal
edge. As a consequence, the standard deviation of the histogram will be large and a
significant volume of CTV voxels will not be safely treated. That however is not the
worse part. The real problem is that under the specific beam modulation the tCTV
will no longer be a large, compact subvolume!. The case shown in Figure 2.20 did not
generate a compact subvolume for values of v < 9% and even for this value, the tCTV
is quite small, meaning that a very large expansion would be necessary. If we agree that
a lower value of v should be used then inevitably we find ourselves in an uncomfortable
position. Did the method fail? Not really. What really failed is the concept of target
expansion as a method to ensure robust dose coverage in the CTV: the PTV concept.
This problem was recently reported by Albertini et al (68). Some of the concepts
developed for conventional photon therapy are being pushed beyond their limits in ion
beam therapy, being this concrete case a good example. As far as the PTV concept
goes, it can be a useful tool to deal with uncertainties in Ion Beam Therapy. However a
more reliable and complete solution to the robustness problem will more likely involve
additional steps in the planning procedure and inverse planning. A good example is
the work of (69, 70, 71, 72), who use robust optimization methods to obtain the beam
spot modulation. These approaches manage to minimize the variance of the dose in the
CTV voxels. A combination of such features with the DTD could hopefully prevent us
from delivering expansions that do not assure their purpose. This is however a topic
for future work and it will be reported elsewhere.
2.3.5 A framework for robust treatment planning in Ion Beam Ther-
apy
In the previous sections it was shown how beam spot modulation, beam arrangement,
treatment plan robustness and PTV definition have intrinsic connections.
The ideas presented above provide not only a tool for creating a margin expansion
but also introduce a conceptual layout to deal with the dependencies in treatment
quality and robustness. It is clear that under this framework, the PTV is not a static
volume define prior to inverse planning and beam arrangement definition but instead
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(a) Beam #1 (b) Beam #2
Figure 2.17: IMPT oblique plan for the prostate case.
(a) Total dose distribution (b) tCTV(m=5%,v=3%)
Figure 2.18: Total dose and tCTV for the IMPT plan of the prostate case.
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(a) Beam #1 (b) Beam #2
Figure 2.19: IMPT horizontal plan for the prostate case.
(a) Total dose distribution (b) tCTV(m=5%,v=9%)
Figure 2.20: Total dose and tCTV for the IMPT plan of the prostate case.
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it it shows its dependencies in a convoluted way. Having this in mind it is fair to ask:
How should the work flow of treatment planning should look like under the DTD?
Figure 2.21 shows a proposal for robust treatment planning in Ion Therapy. It
consist of four phases:
Data acquisition: In this phase the relevant data and information is acquired. Some
of these data are: Patient images from different modalities, contoured CTVs and
OARs, constraints for the OARs, types of uncertainties to be taken into account
along with their probability density function and robustness constraints in the
form of the parameters m and v used in the previous sections. Also, the beam
arrangements are selected here. This could be done manually or by using a beam
angle selection algorithm1. Beam spot modulation is also defined here. This
should be done, ideally, with the assistance of a probabilistic tool for inverse
planning.
Uncertainty propagation: In this phase the histogram of dose calculations is gen-
erated and stored.
Impact on Coverage and Target Expansion: In this phase the impact on CTV
coverage is assessed by the calculation of the tCTV(m,v). Having that, the
PTV(m,v) is also generated iteratively until tCTV (m, v) = CTV .
Clinical assessment and approval: In this phase several aspects are checked for
approval: constrains to the OARs, PTV size and general plan feasibility. If the
requirements are met the plan is approved. If not, the process resets some of the
relevant plan parameters (like beam arrangement) and starts over.
Figure 2.21 shows a differentiation in the type of steps that conform the flowchart.
Boxes in green are meant to be done by a radiation oncologist or therapist. Boxes
in yellow by experienced treatment planner and physicist and boxes in gray are done
automatically under the hood by the treatment planning system.
1This matter will be addressed in Chapter 3.
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Figure 2.21: Flowchart of the proposed planning procedure - Boxes in green are
meant to be done by a radiation oncologist or therapist. Boxes in yellow by experienced
treatment planner and physicist and boxes in gray are done automatically under the hood
by the treatment planning system.
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2.4 Discussion
The need for PTV has been identified and investigated for a long time (57, 58, 60, 61,
62). From its beginning the concept was developed to assure robustness towards CTV
coverage. It is a concept initially developed to mitigate the impact of uncertainties in
conventional photon therapy.
The convenience of the method for 3DCRT and IMRT is probably still an open
question.
Particularly for ion beam therapy with an active delivery system, the standard
expansion rule fails to address the problem of uncertainties. This problem has been
identified and countermeasures are being proposed to reduce the sensitivity of plans
to these errors. Of particular interest is the use of robust inverse planning as done in
(69, 70, 71, 72, 73).
In this chapter a method was proposed to assess if the PTV concept addresses the
issue of robustness and, if so, to reduce the impact of uncertainties on the CTV dose
coverage, under the specific parameters of the plan such like beam spot modulation
and beam angle arrangement.
Having this in mind CTV-to-PTV expansion in ion beam therapy should be a
dynamic process within treatment planning and a result of a successful planning proce-
dure, rather than its starting point. Dynamic Target Definition provides a framework
in which the planner dynamically experiences how PTV size, plan robustness, beam
spot modulation and beam arrangements are convoluted concepts that are depend on
each other. The approach presented here makes it easy to understand the limitations
and the advantages of a treatment modality and of the PTV concept itself.
Several authors have studied the impact of uncertainties on the dose. Unkelbach
and Oelfke (74) used Bayesian inference to assess the impact of organ motion in dose
uncertainties. Maleike et al (75) simulated and visualized dose uncertainties for in-
terfractional motions. Lomax (50) used histograms of dose distributions and assessed
their sensitivity to interfractional errors by analyzing the worst dose scenario obtained
at each voxel.
In this chapter we have used dose histograms for the quantification of the sensitivity
of plan to errors and uncertainties. Once a histogram was generated the values for the
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standard deviation v and the mean deviation m were used. It is worth mentioning
that these values play a crucial role. The use of m=5% and v=3% is due to the fact
that they approximate well the 95%-107% limits for PTV irradiation recommended by
ICRU 50(57). In principle any other choice can be used, if justified. The fact that these
parameters are directly connected to the dose distribution and its uncertainties makes
the overall approach very transparent. The values used for the WEPL uncertainties
presented here are not meant to be used in clinical practice but rather an explanatory
guide on how to apply them once they are known. The basic guideline we used for
deriving such values are based on (16).
It has been discussed in the literature (24, 45, 67) that the technique used for irra-
diation with an active delivery system, whether is SFUD, IMPT or DET has an impact
on plan robustness. Within the DTD approach this means that the generated PTV
will be specific of the technique used. Recently it has been reported (68) that in IMPT
plans requiring high levels of beam spot modulation (like it might be the case if very
hard OAR constraints are applied) the standard concept of CTV-to-PTV margin might
not be enough in order to assure CTV coverage. This is in agreement with the proposed
approach since high levels of modulation without taking into account robustness might
lead to tCTV(m,v) volumes that are too small.
An important question is of course, how an appropriate sparing of healthy tissue can
still be achieved when using this method. In ion beam therapy is usually easier to spare
healthy tissue from medium and low doses as compared to photon treatments. Having
said so, the DTD approach can be connected to an IMPT optimization and/or to a
Beam Angle Optimization algorithm1. Ideally, further consideration on plan robustness
could be added in the beam spot weight optimization process itself as done in (69, 70,
71, 72). By doing so the PTV(m,v) volume generated is expected to be even smaller
while achieving the same level of dose CTV coverage.
It is worth mentioning that since there is a direct connection between the volume
of the PTV(m,v) generated and the robustness of the treatment plan, the size of this
volume becomes a very attractive objective the function for robust optimization. This
1This will be discussed further in Chapter 3
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feature should not be overlooked. One of the main challenges in developing an algo-
rithm for robust optimization is to find an objective function that directly or indirectly
relates to the uncertainties taking into consideration. By using the PTV(m,v) size as
such function we guarantee that any source of uncertainty can be easily taken into
account once it has been characterize with a probability density function. This feature
will be studied further in Chapter 3.
A full Monte Carlo based uncertainty assessment as was done here might not be
always efficient in terms of computing time. In order to realize a histogram of dose val-
ues for each voxel, several forward dose calculations have to be performed which means
that the required calculation time is proportional to the time it takes for a forward dose
calculation. Modern algorithms can perform a forward calculations in seconds which
means that PTV generation can be done within few minutes. Of special interest is the
use of a bootstrap resampling strategy to create the dose histograms. Another way to
attack the problem is to try to calculate directly the uncertainty maps. In some cases
these calculations might be fairly well approximated by analytical expressions. Despite
the fact that each histogram generation involves several dose calculations, the method
converges very fast. The results presented were achieved within two iterations (two sets
of Nmax dose distributions).
The method can be also applied to take into account internal organ motion. The case
is particularly simple for organs in which the motion is periodic and well characterized
by the use of 4D CT.
A constant RBE along the Bragg Peak was used in this chapter. In the last years
authors have discussed how the increasing RBE of protons in their distal end might
cause an ”effective biological range“ larger than expected (76, 77, 78). This scenario
was not treated in this analysis and is left for future investigations.
In DTD range errors which are mainly systematic are treated as random errors.
By randomizing these systematic errors one takes a Bayesian approach in which uncer-
tainty is attached to the degree of belief about a given quantity rather than to random
fluctuations of it. This allows to combine systematic and random errors within an uni-
fied framework. By doing so, one obtains uncertainty maps that allow us to visualize
the degree of belief we can have on dose calculated in each voxel. This is a feature that
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has an immense value and has been pointed out by several authors (74, 75). We believe
it will play an important role in treatment planning in the 21th century.
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3Robust beam angle selection in
Ion Beam Therapy
“If there is a problem you cant solve, then there is an easier problem you can
solve: find it.”
George Polya
This chapter builds on some of the concepts introduced in Chapter 2 to attack a
problem that has gained considerable attention over the last few years: the problem
of beam angle selection. Rather than giving a generic solution for all types of external
radiation therapy, this chapter will treat this problem for the specific case of ion beam
therapy.
3.1 Beam angle selection in radiation therapy
The possibility to rotate the treatment table and the gantry independently opened
up the option to choose beam angles from almost any arbitrary direction. During
many years of conventional radiation therapy, class solutions based on the experience
of the clinicians were used for each specific site of irradiation. From the arrival of
IMRT and the tools for inverse planning, many researches have tried to solve the beam
angle selection problem as an inverse problem. In the literature the term Beam Angle
Optimization (BAO) often refers to it. In the last years the word optimization has
probably been one of the most overused term in treatment planning. The natural
enthusiasm from the successful story of inverse planning in IMRT has led many to
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believe that the BAO problem can be solved by using similar methods. But so far the
problem has proven to be very challenging. The reason is the following: There are two
generic ways to handle the inverse BAO problem:
1. The first way would be to provide an analogous formulation to the inverse IMRT
problem. That is for every beam configuration and every intensity modulation
use the function:
Di = F (~φ1, ~w1, ..., ~φN , ~wN ) (3.1)
where ~φk defines the beam direction of the k
th beam, ~wk is the intensity modu-
lation for that field and Di refers to the dose in an arbitrary voxel.
Using such function F one could, in principle, minimize the deviation of the
dose Di from a desired dose Ddes just like in the familiar problem of intensity
modulation. The main problem is however that the search space for such problem
is enormous. Not only the combinations of beam configurations would have to be
taken into account but also the intensity modulation of every field is dependent
on the beam arrangement itself. From the mathematical point of view this is a
very complex problem.
2. The second strategy involves the use of heuristics approaches to find solutions
without having to navigate in the immense search space of the previous problem.
In this case the merit of a beam angle configuration is often evaluating based on
anatomical or geometrical considerations, avoiding the need of having to perform
a dose calculation for every possible scenario. This way the complexity of the
problem is reduced however the validity of the whole approach depends on the
heuristics used. The choice of an appropriate quantifier of beam angle merit is a
sub-problem that needs to be addressed.
Is easy to understand the complexity of both approaches when looking at what has
been published. Already in the 90’s research on this area was published (79). Often,
researches have put their attention on vigorous methods borrowed from the field of
Machine Learning like stochastic algorithms (80, 81, 82, 83, 84, 85, 86), artificial neural
networks (87) and other modern techniques (88, 89, 90, 91). Recently, Bangert and
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Oelfke (92) proposed a heuristic approach in which they identify clusters of optimal
solutions on the sphere via spherical K-means algorithm.
To make things even more challenging, it has been recognized (45, 50, 70) that (partic-
ularly in ion beam therapy) the issue of plan robustness needs to be taken into account.
Several authors have proposed methods for robust treatment planning. Unkelbach et al
(69, 70) proposed a probabilistic approach for inverse planning in proton therapy while
dealing with the uncertainties in proton range in a generic way. Pflugfelder et al (71)
proposed a worst case optimization to account for range errors and set up uncertain-
ties, similarly Fredriksson et al (72) used a minimax approach to reduced the impact
of uncertainties over large set of possible scenarios and recently Chen et al (73) used
multi criteria optimization (MCO) to find a compromise between dose sparing and plan
robustness1. These works all share that they have not taken beam angle configuration
as input parameter to be optimized.
3.2 A proposal for a robust beam angle selection in Ion
Beam Therapy
Given the nature of the dose deposition of ion beams, beam angle selection plays a
crucial role in the quality and robustness of a treatment. While in IMRT the increased
number of fields and the intensity modulation are used to guarantee steep dose gra-
dients, they also guarantee a high volume of medium and low dose. The situation is
different in particle therapy where very few beams can achieve a conformal dose cover-
age. At the same time if an OAR is irradiated it is because either one of the beams went
through it or it is located in the close vicinity of the target. Geometrical considerations
could prevent at least, the first of these two scenarios.
Geometrical considerations can also enhance plan robustness. For instance some
materials might have a greater uncertainty in their stopping power (or WEPL) than
others. Avoiding going through them would increase the overall robustness of the plan.
As was it shown in the Introduction, the impact of set up errors and movements on
plan robustness is also dependent on the type of interfaces that the beam goes through
1The validity of this approach will be discussed below.
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(44, 45, 50). Avoiding such directions decreases the uncertainty in the position of the
beam spots.
From this perspective it is clear that the strategy of angle selection as way to
enhance robustness is worth investigating. In this section a method for robust beam
angle selection is presented. It can be used for treatment planning using either a passive
or an active delivery system. Here the application of the method on an active delivery
system is limited to the SFUD technique. A discussion on the perspective of the use of
the method for IMPT will be given at the end of the chapter. The method is based on
three postulates that will be followed through the development and implementation of
the algorithm. The three postulates are:
Robustness is a priority : The robustness of a plan is not just a desirable attribute,
it is a mandatory prerequisite. It reduces the space of possible beam and intensity
configurations to a subset upon further optimization can be carried out. If pos-
sible, it should be a hard constraint rather than a soft constraint. To talk about
finding “a compromise between robustness and treatment plan quality (meaning
conformity and healthy tissue sparing in nominal plans)” is in itself a contradic-
tion. The robustness of a plan is a measure of how much can the plan shown
on the screen be trusted. Having a beautiful nominal plan with a compromised
degree of robustness is like being proud of a point estimate while ignoring over-
whelming error bars. In this sense one should be very careful with strategies that
address this problem as multi criteria. One can ask a clinician if he prefers a slight
overdose in the bladder over an overdose in the rectum. That is a compromise.
But uncertainty and degree of belief can not be compromised, never. It is not a
clinical decision, it is a profound epistemological question.
The size of the tCTV is a measure of robustness :1 In Chapter 2 it was pointed
out that the size of the PTV(m,v) was a measure of robustness of the beam
arrangement2. The size of the PTV(m,v) is inversely proportional to size of the
tCTV(m,v). Is given by the number of voxels in the CTV that are not sensible to
errors in terms of dose coverage. It is not a heuristic quantity neither a surrogate
1The tCTV concept is explained in Chapter 2. Here we will refer to the tCTV as the compact set
of voxels safely treated when planning on the CTV. This allow us to find a beam arrangement before
making a PTV expansion. The values of m and v used will be 7%.
2Under a SFUD technique.
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of plan robustness. It defines it. By using the tCTV as measure of robustness we
avoid the need to establish a quantifier of robustness for each of the sources of
uncertainties that are taken into account. The fundamental step is to be able to
give a bayesian characterization of the uncertainties as discussed in Chapter 2.
Beam angle selection and PTV definition should be connected : From a con-
ceptual point of view, if two strategies are used to deal with robustness (beam
angle selection and PTV definition), these strategies should work synchronized.
The PTV concept was born as an early attempt to deal with uncertainties. As
shown in Chapter 2, for two different plans having different levels of robustness,
different PTVs are needed. If a beam selection reduces the impact of uncertain-
ties, an appropriate PTV should be used. Having a generic PTV might in some
situations compromise the dose in structures that are close to the CTV and in
some cases it might not even be an efficient way to mitigate the consequences of
errors.
3.2.1 Objective function for one-beam robust selection
In this paragraph we propose a method to derive the most robust beam configuration.
Let’s call ~φ an arbitrary beam angle direction in a three dimensional geometry. The
vector ~φ has two components: one defining the azimuthal angle and another one defining
the polar angle. The objective function quantifying the value of a given direction in
terms of robustness will be:
RtCTV (~φ) = µ(CTV )− µ(tCTV (m, v, ~φ)) (3.2)
where µ(.) is a function returning the volume of the structure in units of voxels. The
function RtCTV will have values ranging from zero to the number of voxels found in
the CTV. The task is to find such ~φ∗ that:
~φ∗tCTV = arg min
~φ∈S2
RtCTV (~φ) (3.3)
Minimizing function RtCTV brings a computational challenge. For every beam
direction one would have to generate a histogram of dose calculations as the ones done
in Chapter 2. For that reason it is useful to find a second function Rs that behaves like
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RtCTV does, that is, that increases as RtCTV , decreases as RtCTV decreases and have
the local and global extremes in the same points in search space.
Let’s assume that a given beam uses M beam spots. The position of the jth beam
spot in a nominal plan will be given by the vector ~s0j . Let’s describe the errors and
uncertainties by using probability density functions. If we sample one instance of these
errors (such as set up or range errors) and calculate the location of the jth beam spot
under that realization of that error then we will obtain a new vector for the location
~skj , where k stands for the k
th random realization of the errors.
The quantity
σ2k =
∑M
j
∣∣∣∣∣∣~s0j − ~sjk∣∣∣∣∣∣2
M
(3.4)
will give us a measure of the displacement all the beam spots under that given
random realization of the error. Here M is the number of beam spots used. The
average value the quantity σ2k over Nmax random realizations will define the function
Rs:
Rs(~φ) =
√∑Nmax
k σ
2
k
Nmax
(3.5)
It is not hard to see why the function Rs(.) is used as a generic surrogate of the
function RtCTV (.). Any instance of a random realization of an error (whether it is a
range error or a set up error or a motion of the organ or any other) leads to a shift
in the location of the Bragg peaks within an internal frame of reference. In order to
estimate the shift, the vector ~sjk is calculated using a simple ray-tracing algorithm.
The computational advantages lays in the fact that doing ray-tracing calculation for
one point is much faster than performing a dose calculation for hundreds of voxels. The
impact of the uncertainty on the final deviation of the dose from the one expected will
generally speaking increase or decrease with the magnitude of the shift of the beam
spots. This strategy allows us to use the same method for a wide range of errors and
uncertainties.
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Ignoring any other criteria, like healthy tissue sparing, the most robust beam angle
selection for one beam would then be:
~φ∗s = arg min
~φ∈S2
Rs(~φ) (3.6)
3.2.2 Objective function for multiple beams robust selection
To generalize the method to a arrangement of n beams, lets assume that the function
3.4 is evaluated for n beam angles. Let σ2kl be the value of such function for the l
th
beam.
Each instance of an error will affect different beams in a different way. For a given
beam arrangement and a given realization of an uncertainty the most affected beam
will be the one having the highest σ2k. This value will be referred as:
σmaxk = max{σ2k1, σ2k2, ..., σ2kn} (3.7)
Similar to the one-beam case, the objective function proposed is:
RMaxs (
~φ1, ~φ2, ..., ~φn) =
√∑Nmax
k σ
max
k
Nmax
(3.8)
By minimizing this function we are practically following a minimax optimization.
3.2.3 Accounting for Organs at Risk
As opposed to photon therapy where a large volume receives medium and low doses,
the tissue irradiated in ion beam therapy is located either in the entrance region of the
beam or near the target volume. To minimize the irradiation of a healthy structure it
is enough to avoid irradiating through it and avoid having beam spots stopping in front
of it. If the only constraint to the OAR is a maximal dose constraint and the structure
is located far from the target then in principle one could allow a beam to go through
it as long as the dose remains below the limit. This situation is however uncommon in
ion beam therapy.
The strategy for OAR sparing used here is the following:
Avoid going through organs at risk : This will avoid large volumes of medium
and low dose in the healthy structure. This procedure can be automatized fairly
65
3. ROBUST BEAM ANGLE SELECTION IN ION BEAM THERAPY
easy. To achieve this Ja¨kel and Debus (93) used a cylindrical projection of the
healthy structures on the sphere of beam angle directions. Similarly Cabal et
al (7) counted the number of OAR voxels through which a given beam goes.
By doing so one takes advantage of the specific pattern of dose deposition by ion
beams which allows to choose angles without having to perform a dose calculation.
Penalize harder beam spots shifts near the OAR : In some difficult cases the
OAR is next to the target. Set up errors or errors in the estimation of the range
of the particle might not only affect the dose coverage but also compromise the
sparing of the OAR. Having this in mind equation 3.4 becomes:
σ2k =
∑M
j βj
∣∣∣∣∣∣~s0j − ~sjk∣∣∣∣∣∣2
M
(3.9)
where βj = 1 if the j
th beam spot is not in the close vicinity of the OAR and
βj = β > 1 if it does. By doing so we are avoiding high uncertainty regions
near the OAR. This is an important feature when using the DTD approach for
PTV definition: avoiding high uncertainty regions near the OARs reduces the
chances of having PTVs that expand onto it. This process is a generalization of
the common practice of avoiding beam that stop right in front of an OAR.
3.2.4 The optimization algorithm
The function Rs is generally speaking a non-convex function with multiple local minima.
Figure 3.2 shows this feature for a two dimensional Head and Neck. The search for
global minima is then a difficult task. However if we focus our attention only in those
regions of the search space that are clinically feasible and do not go through organs
at risk the size of it reduces considerably. Ja¨kel and Debus (93) have shown that for
a Head and Neck case the subspace of usable beam directions are just a fraction of
the whole sphere. Moreover, they showed that from a clinical point of view the best
beam configurations are clustered in compact regions of this subspace. For this reason
we used a Newton algorithm to minimize function RMaxs . The optimization was run
locally in several subregions of the sphere.
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3.3 A Head and Neck case
In order to exemplify the ideas discussed in the previous section they will be applied
to the Head an Neck case shown in Figure 3.1.
The calculations will be done only in one CT slice so they can be regarded as two
dimensional case. There are five critical structures identified: the eyes, the optic nerves
and the brain stem. The target volume delineated in green is the CTV. The task is
to find a robust beam arrangement of two beams while minimizing the dose in the
OARs using a SFUD technique. Then to propose a PTV expansion for such beam
arrangement. Notice that the distance between the CTV and the brain stem is only 1
mm.
Figure 3.1: Head and Neck case - CTV is delineated in green, brain stem in blue and
eyes and optic nerves in red.
In order to see the relationship between the function RtCTV and its surrogate Rs
their values are plot for 24 equidistant locations. In the evaluation of the function for
Figure 3.2 organs at risk were not taken into account. Although we do not make use
of the function RtCTV the correlation between Rs and RtCTV is shown in Figures 3.2
and 3.3.
Figure 3.2 shows how both functions depend on the beam angle in a similar way.
Their local and global extremes are located in the same points. Figure 3.3 shows that,
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Figure 3.2: RtCTV and Rs for the Head and Neck case - The functions are evaluated
in 24 equidistant points
Figure 3.3: RtCTV vs. Rs - Each point corresponds to a one-beam configuration for the
24 angles shown in the previous figure.
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although there is not a one-to-one relationship between both functions their correlation
is strong.
In order to look for a robust two beam configuration the function RMaxs needs to
be used. Again a comparison between this function and the function RtCTV (now for
two beam arrangements) is shown in Figure 3.4.
Figure 3.4: RtCTV vs. R
Max
s - Each point corresponds to a two-beam configuration.
The red square shows the most robust configurations.
The algorithm was run three times with three different settings:
1. In the first setting OAR were disregarded and the task was to find the most
robust beam configuration towards CTV dose coverage. In this case the beam
angles were discretized with a separation of 15 degrees. 276 configurations were
evaluated and a local search in each of these configurations was made. The best
beam arrangement obtained was φ1 = 88 degrees and φ2 = 74 degrees.
2. In the second task directions going through an OAR were avoided but no extra
penalization was given to beam spot shifts near the OAR. Only fifteen initial
beam configurations were allowed. A local search was performed in each of the
feasible scenarios. The size of the search space was now around 20% of its original
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size. The best beam arrangement obtained was φ1 = 286 degrees and φ2 = 304
degrees.
3. Finally the algorithm was run with the same search space as in the second task
but using a penalization factor of β = 10 as in equation 3.9, for those beam spots
that are within 5 mm of the OAR. The best beam arrangement obtained was
φ1 = 285 degrees and φ2 = 75 degrees.
Figure 3.5 shows the tCTV for the first solution (φ1 = 88 degrees and φ2 = 74
degrees). Since OARs were disregarded in this run it uses a beam (φ1 = 88 degrees)
that goes through an organ at risk. This can be observed on the dose volume histogram
in Figure 3.9. Although the impact of uncertainties was not very high, the fact that
the beam went through the OAR produced large volumes of medium-to-high dose in it.
The tCTV for the second solution (φ1 = 286 degrees and φ2 = 304 degrees) is shown
in Figure 3.6. This beam configuration obviously avoids going through OARs (since
this regions were excluded from search space) but places a high uncertainty region in
front of the brain stem as can be seen from the figure. This can also be appreciated in
the DVH shown in Figure 3.10. The fact that in the nominal plan a large number of
particle are stopping in front of the OAR makes its dose assessment very uncertain, as
reflected by the high fluctuations of the DVHs.
Finally Figure 3.7 shows the third solution obtained (φ1 = 285 degrees and φ2 = 75
degrees). One can see that having a penalty factor for the CTV voxels close tho the
OAR reduced the uncertainty in them. This reflected not only in lowering the volumes
of medium-to-high dose in the OAR (which was achieved thanks to the fact that some
beam angles were avoided) but also it shows a robust assessment of the dose in the
OAR as can be seen in Figure 3.11. It is interesting that the third solution was slightly
more robust for CTV coverage than the second solution. The reason for this is that in
the second solution most of the beam spots that carry the largest uncertainty are also
stopping in front of the OAR. For this reason penalizing them has a two fold effect.
The third solution exemplifies the algorithm proposed here and in that sense it is the
solution it produces for this case. These results are summarized in Tables 3.1 and 3.2
and
The PTV defined for the optimal beam arrangement is shown in Figure 3.8.
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Figure 3.5: Robustness analysis for Solution 1 - The beam angles used were 88
degrees and 74 degrees. Red voxels define the tCTV.
Figure 3.6: Robustness analysis for Solution 2 - The beam angles used were 286
degrees and 304 degrees. Red voxels define the tCTV.
Angles Average min. dose CTV Average max. dose CTV
74-88 93% (88,96) 106% (102,118)
286-304 92% (76,95) 108% (104,118)
75-285 93% (68,96) 107% (104,112)
Table 3.1: The results reflect the CTV coverage. Number in parenthesis are minimal and
maximal values obtained form the histograms.
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Figure 3.7: Robustness analysis for Solution 3 - The beam angles used were 75
degrees and 285 degrees. Red voxels define the tCTV.
Figure 3.8: PTV expansion for the optimal case - The PTV structure for the optimal
case using DTD is shown in cyan.
Angles Average max. dose OAR 50% isodose volume OAR
74-88 104% (99,108) 96% (93,100)
286-304 106% (101,112) 78% (60,100)
75-285 98% (96,103) 80% (76,88)
Table 3.2: Results reflect OAR dose impact. Number in parenthesis are minimal and
maximal values obtained form the histograms.
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3.3 A Head and Neck case
Figure 3.9: Dose Volume Histogram for solution 1 - Only robustness was taken
into account. Angles obtained were 88 degrees and 74 degrees. Green lines are the DVHs
of OAR, blue lines the DVH of the CTV.
Figure 3.10: Dose Volume Histogram for solution 2 - Directions going through and
OAR were avoided. Angles obtained were 286 degrees and 304 degrees. Green lines are
the DVHs of OAR, blue lines the DVH of the CTV.
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Figure 3.11: Dose Volume Histogram for solution 3 - Directions going through
and OAR were avoided and shifts of beam spots near the OAR highly penalized. Angles
obtained were 285 degrees and 75 degrees. Green lines are the DVHs of OAR, blue lines
the DVH of the CTV.
3.4 Discussion
The motivation for the use of the function Rs as a surrogate of the function RtCTV is
based on the fact the it is faster to compute. In fact, while RtCTV requires a histogram
of dose calculations the function Rs requires a ray tracing operation for the location
of each beam spot. In computing Rs no assumptions whatsoever about Bragg peak
degradation or lateral scattering of the particles is made in order to keep the calculation
as efficient as possible. One could go one step further and apply the Rs function only to
those beam spots that are located in the distal end of the target. This approach was not
tried in this work but it is expected to reduced the calculation times since the amount
of ray tracing operations would reduce from being proportional to the target volume
to being proportional to the projection of the target onto the plane perpendicular to
the beam direction.
Obviously the function RtCTV also depends on the values m and v for defining if
a voxel is safely treated. We however noticed that for values below 15% the shape of
the RtCTV function was nearly the same. We chose values of m = v = 7% for beam
arrangement selection and m = 5%, v = 3% for target expansion.
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In the platform used for this work (PartPlan) there is a significant difference in time
between a dose calculation and a beam spot shift operation. While the dose calculation
for protons takes about 3 minutes (for the case shown in this chapter), a beam spot
shift is computed within few seconds. For a given direction, a full histogram of beam
spot shifts using Nmax = 50 realizations took between one and two minutes.
Although the problem was addressed here using local optimization, it is expected
that having a global solver or addressing the issue of the combinatorial character of the
problem might improve the results. Having said so the most valuable part of this work
is not how the minimization is done from a mathematical point of view but how we
have managed to define the problem in harmony with the concept of PTV presented
in Chapter 2. Further work aiming to look for global solutions is necessary.
As the reader might have noticed, the number of fields used was predefined by the
user. Since their number is usually low (rarely larger than four or five) one could run
the algorithm individually for each predefined number of beams.
Another important question is how to expand the method to IMPT plans. It is
worth noticing that the functions Rs and R
Max
s penalize only beam spot shifts and are
not dependent on their intensity. In this sense it is reasonable to think that they will
work well for any type of beam spot modulation and preliminary results support this
belief, however more work is needed to understand in which scenarios the strategy is
adequate and how to merge it with DTD.
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4.1 Summary
Some of the fundamental ideas of Ion Beam Therapy were introduced in Chapter 1.
This introduction was not meant to be a detailed reference of the state-of-art of the
field but instead a compact overview of the concepts that were relevant for the following
chapters. The technicalities were, for most of the topics, intentionally avoided.
In Chapter 2 the problem of PTV definition in Ion Beam Therapy was addressed.
Section 2.1 introduced some of the most relevant concepts used for treatment planning
as they are discussed in the ICRU reports 50, 62 and 78(57, 58, 59). In Section 2.2 the
convenience of the use of PTV concept as presented in the ICRU 50 was questioned.
With counter-examples it was shown that some of the basic requirements for the use of
these concepts are not met in Ion Beam Therapy. Section 2.3 proposed new concepts
for robust treatment planning in Ion Beam Therapy. These are:
tCTV(m,v): The subvolume of CTV voxels that were not affected by errors and
uncertainties.
PTV(m,v): The volume expansion that assures that tCTV (m, v) = PTV
Robust Conformity: The concept of conformity in the presence of uncertainties. The
indexes R and C, referred to as, Robust Conformity Indexes were proposed as
quantifiers of robust conformity.
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Building on these concepts a novel method for PTV definition was proposed: Dy-
namic Target Definition (DTD). These ideas were applied and exemplified with a two
dimensional Head and Neck case and a two dimensional Prostate case.
Section 2.3.4 discussed the applicability of the PTV concept for IMPT. It was shown
that for IMPT the PTV concept by itself does not assure robust CTV dose coverage
and a combination of the DTD approach with additional techniques, some of which
have been published (69, 70, 71, 72) might help to tackle the problem of robustness for
this technique.
Section 2.3.5 presented a framework for treatment planning in Ion Beam Therapy
that is developed around the methods and concepts proposed in the previous sections
and gives special emphasis on the robustness of the treatment plan.
Chapter 3 focuses on the problem of beam angle selection for Ion Beam Therapy.
Section 3.1 discusses the complexity of the problem and explains the strategies com-
monly found in published algorithms. In Section 3.2 we make a contribution to the
problem of beam angle selection in Ion Beam Therapy. Building on the same line of
thought we placed robustness as the main priority when choosing a beam arrangement.
The proposed method builds on the concept of tCTV presented in Chapter 2. We
argued that tCTV is a dynamic measure or robustness for a given plan. Based on that
we proposed the function
RtCTV (~φ) = µ(CTV )− µ(tCTV ) (4.1)
as a measure of the merit of a one-beam arrangement. Because this function requires
significant computation times we define a secondary function that Rs that behaves in
a similar fashion while being much faster to compute. A generalization to a multiple
beam arrangement was made through the introduction of the function RMaxs . Finally
an strategy to take into account OAR sparing is proposed. It consists of two aspects:
avoiding going through OAR and avoiding having high uncertainty regions near the
OAR. The first aspect prevents the OAR from receiving low-to-medium doses while
the second aspect prevents that uncertainties would have a negative impact on the
healthy structure.
These ideas are exemplified in Section 3.3 with a two dimensional Head and Neck
case.
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4.2 Novelty
The main contribution of this work is to define a conceptual layout to deal with un-
certainties in treatment planning with Ion Beams. From this conceptual layout two
problems were then addressed: The problem of PTV definition in particle therapy and
the problem of beam angle selection. Both questions are considered to be open prob-
lems by the international community of particle therapy practitioners and researchers.
The methods developed here give at least partial solutions to these problems and allow
us to have a better understanding of them.
4.3 Outlook
The work carried out through this thesis has led to a better understanding of some
of the challenges of robust treatment planning with Ion Beams. The following aspects
remain as problems to be addressed and studied in the future:
4.3.1 IMPT
A combination of the presented methods with robust inverse planning for IMPT is
desirable. This will allow us to fully understand the magnitude of the challenges and
exploit the benefits of this technique, safely. Some authors have suggested (68) that
the traditional PTV concept fails in IMPT. While it is true that conventional methods
might not always work in Ion Beam Therapy (as was shown here), the issue with IMPT
is robustness. Certain tools might be useful in some situations but generally speaking,
if a given plan is highly sensible to errors probably the only countermeasure reasonable
is to design a different plan. Having said so we believe that the DTD together with
the proposed beam angle selection algorithm and the robust inverse planning work
published in the literature (69, 70, 71, 72) will provide a powerful set of tools to navigate
through the possibilities of robust inverse planning for IMPT.
4.3.2 Target definition on High LET modalities
The methods developed in this work focused on proton beams delivered with an active
system. It was assumed that the RBE was constant along the Bragg Peak. A gener-
alization of the concepts to a non-constant RBE scenario and specially to Carbon Ion
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beams is interesting. Although in principle the same methods can be used just by eval-
uating the RBE-weighted-dose instead of the absorbed dose a more elegant alternative
would be to use the concept of radiobiological effect instead of the dose. Under this
scenario instead of having a histogram of dose distributions one would have a histogram
of effect distributions1. The tCTV would be evaluated by analyzing the fluctuations of
the effect in each voxel, just like explained in Chapter 2. This way would also allow to
take into consideration the uncertainties of the radiobiological modeling, namely the
uncertainties of α and β, if using the LQ model.
The final question to ask would be: “Should CTV-to-PTV expansions be the same
for proton and carbon ion plans?”
In addition, it has been shown and discussed in the literature (76, 77, 78) that
for protons, the use of a constant RBE might lead to an important underestimation
of the effect in the distal part of the beam. Applying the DTD framework with an
effect-based-approach would allow us to understand better how distal margins should
be defined.
4.3.3 Robust comparison between particle and photon treatments
As medical physicist very often we find ourselves in front of comparisons between photon
and ion beam plans which make an effort to show the obvious dosimetric advantage
of ion beams as compared to photons. Two or three decades ago, when all proton
treatments were done with passive delivery systems and most of the photon treatments
were done with old-fashion conventional equipment, there was no discussion that proton
therapy had a clear advantage in terms of conformity and integral doses.
However, in the last twenty years photon therapy has had an tremendous revolution
in equipment and software. The ability to tailor steep dose gradients near the target
has evolved to a point that today it is not a unique feature, anymore, of Ion Beam
therapy.
We can go one step further and ask: “How does the robust conformity of both
modalities compare?”. It is clear that in order to make a fair dosimetric comparison
between both modalities is not enough to compare nominal plans. For the comparison
to be fair one would have to take into account the degree of belief attached to a given
dose distribution.
1In the absence of a better term.
80
4.3 Outlook
Conducting a study in which the DTD approach is applied to photon and ion beam
plans would certainly give us a profound insight on this question.
4.3.4 Clinical implementation
Finally, a clinical implementation of the methods developed in this work is perhaps the
most important step to consider. This implementation should probably be carried out
in three stages: First it needs to be implemented in the TPS of a facility offering ion
beam therapy. After doing so, a study have to be conducted on phantoms to validate the
methods and understand their application in a clinical scenario. Finally and assuming
the first two stages were successful, the methodology should be deployed into daily
clinical practice. This is an ambitious task that would require the commitment and
engagement of a large team of people who see the benefits on doing so. The work
presented here suggest that by doing so we could provide ion beam treatments that are
more robust towards CTV coverage while irradiating “just the right“ amount of healthy
tissue. This could potentially translate into an enhanced tumor control probability and
a reduction of some of the side effects that this kind of therapy usually brings along.
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